10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to            

Commission File Number: 001-35568 (Healthcare Trust of America, Inc.)

Commission File Number: 333-190916 (Healthcare Trust of America Holdings, LP)

_________________________ 

HEALTHCARE TRUST OF AMERICA, INC.

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

(Exact name of registrant as specified in its charter)

Maryland (Healthcare Trust of America, Inc.)	20-4738467
Delaware (Healthcare Trust of America Holdings, LP)	20-4738347
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

16435 N. Scottsdale Road, Suite 320

Scottsdale, Arizona 85254

(Address of principal executive offices)

(480) 998-3478

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    

Healthcare Trust of America, Inc.	x Yes	¨No
Healthcare Trust of America Holdings, LP	x Yes	¨No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    

Healthcare Trust of America, Inc.	x Yes	¨No
Healthcare Trust of America Holdings, LP	x Yes	¨No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Healthcare Trust of America, Inc.	Large-accelerated filer x	Accelerated filer ¨	Non-accelerated filer ¨	Smaller reporting company ¨
			(Do not check if a smaller reporting company)
Healthcare Trust of America Holdings, LP	Large-accelerated filer ¨	Accelerated filer ¨	Non-accelerated filer x	Smaller reporting company ¨
			(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   

Healthcare Trust of America, Inc.	¨Yes	x No
Healthcare Trust of America Holdings, LP	¨Yes	x No

As of October 24, 2016, there were 141,727,903 shares of Class A common stock of Healthcare Trust of America, Inc. outstanding.

Explanatory Note

This Quarterly Report combines the Quarterly Reports on Form 10-Q (“Quarterly Report”) for the quarter ended September 30, 2016 of Healthcare Trust of America, Inc. (“HTA”), a Maryland corporation, and Healthcare Trust of America Holdings, LP (“HTALP”), a Delaware limited partnership. Unless otherwise indicated or unless the context requires otherwise, all references in this Quarterly Report to “we,” “us,” “our,” “the Company” or “our Company” refer to HTA and HTALP, collectively, and all references to “common stock” shall refer to the Class A common stock of HTA.

HTA operates as a real estate investment trust (“REIT”) and is the general partner of HTALP. As of September 30, 2016, HTA owned a 97.0% partnership interest in HTALP, and other limited partners, including some of HTA’s directors, executive officers and their affiliates, owned the remaining partnership interest (including the long-term incentive plan (“LTIP”) units) in HTALP. As the sole general partner of HTALP, HTA has the full, exclusive and complete responsibility for HTALP’s day-to-day management and control, including its compliance with the Securities and Exchange Commission (“SEC”) filing requirements.

We believe it is important to understand the few differences between HTA and HTALP in the context of how we operate as an integrated consolidated company. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP. As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP, issuing public equity from time to time and guaranteeing certain debts of HTALP. HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity. Except for net proceeds from public equity issuances by HTA, which are generally contributed to HTALP in exchange for partnership units of HTALP, HTALP generates the capital required for the business through its operations and by direct or indirect incurrence of indebtedness or through the issuance of its partnership units.

Noncontrolling interests, stockholders’ equity and partners’ capital are the primary areas of difference between the condensed consolidated financial statements of HTA and HTALP. Limited partnership units in HTALP are accounted for as partners’ capital in HTALP’s condensed consolidated balance sheets and as noncontrolling interest reflected within equity in HTA’s condensed consolidated balance sheets. The differences between HTA’s stockholders’ equity and HTALP’s partners’ capital are due to the differences in the equity issued by HTA and HTALP, respectively.

The Company believes combining the Quarterly Reports of HTA and HTALP, including the notes to the condensed consolidated financial statements, into this single Quarterly Report results in the following benefits:

• enhances stockholders’ understanding of HTA and HTALP by enabling stockholders to view the business as a whole in the same manner that management views and operates the business;

• eliminates duplicative disclosure and provides a more streamlined and readable presentation since a substantial portion of the disclosure in this Quarterly Report applies to both HTA and HTALP; and

• creates time and cost efficiencies through the preparation of a single combined Quarterly Report instead of two separate Quarterly Reports.

In order to highlight the material differences between HTA and HTALP, this Quarterly Report includes sections that separately present and discuss areas that are materially different between HTA and HTALP, including:

• the condensed consolidated financial statements;

• certain accompanying notes to the condensed consolidated financial statements, including Note 7 - Debt, Note 10 - Stockholders’ Equity and Partners’ Capital, Note 12 - Per Share Data of HTA and Note 13 - Per Unit Data of HTALP;

• the Funds From Operations (“FFO”) and Normalized FFO in Part 1, Item 2 of this Quarterly Report;

• the controls and procedures in Part 1, Item 4 of this Quarterly Report; and

• the certifications of the Chief Executive Officer and the Chief Financial Officer included as Exhibits 31 and 32 to this Quarterly Report.

In the sections of this Quarterly Report that combine disclosure for HTA and HTALP, this Quarterly Report refers to actions or holdings as being actions or holdings of the Company. Although HTALP (directly or indirectly through one of its subsidiaries) is generally the entity that enters into contracts, holds assets and issues or incurs debt, management believes this presentation is appropriate for the reasons set forth above and because the business of the Company is a single integrated enterprise operated through HTALP.

2

HEALTHCARE TRUST OF AMERICA, INC. AND

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

TABLE OF CONTENTS

		Page
PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	4
Healthcare Trust of America, Inc.
	Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015	4
	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2016 and 2015	5
	Condensed Consolidated Statements of Equity for the Nine Months Ended September 30, 2016 and 2015	6
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and 2015	7
Healthcare Trust of America Holdings, LP
	Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015	8
	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2016 and 2015	9
	Condensed Consolidated Statements of Changes in Partners’ Capital for the Nine Months Ended September 30, 2016 and 2015	10
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and 2015	11
Notes for Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP
	Notes to Unaudited Condensed Consolidated Financial Statements	12
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	36
Item 4.	Controls and Procedures	36
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	38
Item 1A.	Risk Factors	38
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	38
Item 6.	Exhibits	38
Signatures		39

3

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

	September 30, 2016			December 31, 2015
ASSETS
Real estate investments:
Land	$	381,745		$	303,706
Building and improvements	3,406,897			2,901,157
Lease intangibles	466,434			430,749
	4,255,076			3,635,612
Accumulated depreciation and amortization	(779,378		)	(676,144		)
Real estate investments, net	3,475,698			2,959,468
Cash and cash equivalents	17,938			13,070
Restricted cash and escrow deposits	13,689			15,892
Receivables and other assets, net	160,837			141,703
Other intangibles, net	47,728			42,167
Total assets	$	3,715,890		$	3,172,300
LIABILITIES AND EQUITY
Liabilities:
Debt	$	1,712,598		$	1,590,696
Accounts payable and accrued liabilities	104,202			94,933
Derivative financial instruments - interest rate swaps	4,866			2,370
Security deposits, prepaid rent and other liabilities	44,828			46,295
Intangible liabilities, net	36,928			26,611
Total liabilities	1,903,422			1,760,905
Commitments and contingencies
Redeemable noncontrolling interests	9,215			4,437
Equity:
Preferred stock, $0.01 par value; 200,000,000 shares authorized; none issued and outstanding	—			—
Class A common stock, $0.01 par value; 1,000,000,000 shares authorized; 141,728,448 and 127,026,839 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	1,417			1,270
Additional paid-in capital	2,753,566			2,328,806
Cumulative dividends in excess of earnings	(1,042,977		)	(950,652		)
Total stockholders’ equity	1,712,006			1,379,424
Noncontrolling interests	91,247			27,534
Total equity	1,803,253			1,406,958
Total liabilities and equity	$	3,715,890		$	3,172,300

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Revenues:
Rental income	$	118,252		$	103,875		$	338,646		$	301,570
Interest and other operating income	88			67			243			203
Total revenues	118,340			103,942			338,889			301,773
Expenses:
Rental	36,885			32,921			105,299			92,855
General and administrative	7,293			6,430			20,879			19,229
Acquisition-related	1,122			907			4,997			3,365
Depreciation and amortization	47,864			40,518			130,430			115,179
Impairment	—			—			—			1,655
Total expenses	93,164			80,776			261,605			232,283
Income before other income (expense)	25,176			23,166			77,284			69,490
Interest expense:
Interest related to derivative financial instruments	(552		)	(903		)	(1,856		)	(2,278		)
Gain (loss) on change in fair value of derivative financial instruments, net	1,306			(2,383		)	(2,144		)	(3,079		)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments	754			(3,286		)	(4,000		)	(5,357		)
Interest related to debt	(16,386		)	(13,536		)	(44,503		)	(41,499		)
Gain on sale of real estate, net	—			152			4,212			152
(Loss) gain on extinguishment of debt, net	(3,000		)	(14		)	(3,022		)	107
Other income	95			72			220			91
Net income	$	6,639		$	6,554		$	30,191		$	22,984
Net income attributable to noncontrolling interests (1)	(212		)	(91		)	(830		)	(425		)
Net income attributable to common stockholders	$	6,427		$	6,463		$	29,361		$	22,559
Earnings per common share - basic:
Net income attributable to common stockholders	$	0.05		$	0.05		$	0.22		$	0.18
Earnings per common share - diluted:
Net income attributable to common stockholders	$	0.04		$	0.05		$	0.21		$	0.18
Weighted average common shares outstanding:
Basic	138,807			126,863			134,905			125,750
Diluted	143,138			128,793			138,314			127,680
Dividends declared per common share	$	0.300		$	0.295		$	0.890		$	0.875
(1) Includes amounts attributable to redeemable noncontrolling interests.

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(In thousands)

(Unaudited)

	Class A Common Stock					Additional Paid-In Capital			Cumulative Dividends in Excess of Earnings			Total Stockholders’ Equity			Noncontrolling Interests			Total Equity
	Shares		Amount
Balance as of December 31, 2014	125,087		$	1,251		$	2,281,932		$	(836,044	)	$	1,447,139		$	29,282		$	1,476,421
Issuance of common stock	1,800		18			43,631			—			43,649			—			43,649
Share-based award transactions, net	200		2			4,460			—			4,462			—			4,462
Repurchase and cancellation of common stock	(49	)	(1		)	(1,321		)	—			(1,322		)	—			(1,322		)
Dividends declared	—		—			—			(110,071		)	(110,071		)	(1,695		)	(111,766		)
Net income	—		—			—			22,559			22,559			348			22,907
Balance as of September 30, 2015	127,038		$	1,270		$	2,328,702		$	(923,556	)	$	1,406,416		$	27,935		$	1,434,351
Balance as of December 31, 2015	127,027		$	1,270		$	2,328,806		$	(950,652	)	$	1,379,424		$	27,534		$	1,406,958
Issuance of common stock, net	14,138		141			417,022			—			417,163			—			417,163
Issuance of operating partnership units in connection with an acquisition	—		—			—			—			—			71,754			71,754
Share-based award transactions, net	393		4			5,132			—			5,136			—			5,136
Repurchase and cancellation of common stock	(87	)	(1		)	(2,424		)	—			(2,425		)	—			(2,425		)
Redemption of noncontrolling interest and other	257		3			5,030			—			5,033			(5,709		)	(676		)
Dividends declared	—		—			—			(121,686		)	(121,686		)	(3,134		)	(124,820		)
Net income	—		—			—			29,361			29,361			802			30,163
Balance as of September 30, 2016	141,728		$	1,417		$	2,753,566		$	(1,042,977	)	$	1,712,006		$	91,247		$	1,803,253

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2016			2015
Cash flows from operating activities:
Net income	$	30,191		$	22,984
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	128,728			112,711
Share-based compensation expense	5,136			4,462
Bad debt expense	508			743
Gain on sale of real estate, net	(4,212		)	(152		)
Impairment	—			1,655
Loss (gain) on extinguishment of debt, net	3,022			(107		)
Change in fair value of derivative financial instruments	2,144			3,079
Changes in operating assets and liabilities:
Receivables and other assets, net	(14,051		)	(6,021		)
Accounts payable and accrued liabilities	3,598			(4,124		)
Prepaid rent and other liabilities	(6,807		)	3,429
Net cash provided by operating activities	148,257			138,659
Cash flows from investing activities:
Investments in real estate	(532,527		)	(253,107		)
Proceeds from the sale of real estate	23,368			33,279
Capital expenditures	(34,064		)	(17,330		)
Restricted cash, escrow deposits and other assets	2,143			2,994
Net cash used in investing activities	(541,080		)	(234,164		)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	513,000			387,000
Payments on unsecured revolving credit facility	(704,000		)	(247,000		)
Proceeds from unsecured senior notes	347,725			—
Borrowings on unsecured term loans	200,000			100,000
Payments on unsecured term loans	(155,000		)	—
Payments on secured mortgage loans	(98,453		)	(76,149		)
Deferred financing costs	(3,039		)	(289		)
Security deposits	862			145
Proceeds from issuance of common stock	418,891			44,324
Repurchase and cancellation of common stock	(2,425		)	(1,322		)
Dividends paid	(116,655		)	(108,891		)
Distributions paid to noncontrolling interest of limited partners	(2,724		)	(1,580		)
Redemption of redeemable noncontrolling interest	(491		)	—
Net cash provided by financing activities	397,691			96,238
Net change in cash and cash equivalents	4,868			733
Cash and cash equivalents - beginning of period	13,070			10,413
Cash and cash equivalents - end of period	$	17,938		$	11,146

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except unit data)

(Unaudited)

	September 30, 2016			December 31, 2015
ASSETS
Real estate investments:
Land	$	381,745		$	303,706
Building and improvements	3,406,897			2,901,157
Lease intangibles	466,434			430,749
	4,255,076			3,635,612
Accumulated depreciation and amortization	(779,378		)	(676,144		)
Real estate investments, net	3,475,698			2,959,468
Cash and cash equivalents	17,938			13,070
Restricted cash and escrow deposits	13,689			15,892
Receivables and other assets, net	160,837			141,703
Other intangibles, net	47,728			42,167
Total assets	$	3,715,890		$	3,172,300
LIABILITIES AND PARTNERS’ CAPITAL
Liabilities:
Debt	$	1,712,598		$	1,590,696
Accounts payable and accrued liabilities	104,202			94,933
Derivative financial instruments - interest rate swaps	4,866			2,370
Security deposits, prepaid rent and other liabilities	44,828			46,295
Intangible liabilities, net	36,928			26,611
Total liabilities	1,903,422			1,760,905
Commitments and contingencies
Redeemable noncontrolling interests	9,215			4,437
Partners’ Capital:
Limited partners’ capital, 4,323,095 and 1,929,942 units issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	90,977			27,264
General partners’ capital, 141,728,448 and 127,026,839 units issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	1,712,276			1,379,694
Total partners’ capital	1,803,253			1,406,958
Total liabilities and partners’ capital	$	3,715,890		$	3,172,300

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per unit data)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Revenues:
Rental income	$	118,252		$	103,875		$	338,646		$	301,570
Interest and other operating income	88			67			243			203
Total revenues	118,340			103,942			338,889			301,773
Expenses:
Rental	36,885			32,921			105,299			92,855
General and administrative	7,293			6,430			20,879			19,229
Acquisition-related	1,122			907			4,997			3,365
Depreciation and amortization	47,864			40,518			130,430			115,179
Impairment	—			—			—			1,655
Total expenses	93,164			80,776			261,605			232,283
Income before other income (expense)	25,176			23,166			77,284			69,490
Interest expense:
Interest related to derivative financial instruments	(552		)	(903		)	(1,856		)	(2,278		)
Gain (loss) on change in fair value of derivative financial instruments, net	1,306			(2,383		)	(2,144		)	(3,079		)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments	754			(3,286		)	(4,000		)	(5,357		)
Interest related to debt	(16,386		)	(13,536		)	(44,503		)	(41,499		)
Gain on sale of real estate, net	—			152			4,212			152
(Loss) gain on extinguishment of debt, net	(3,000		)	(14		)	(3,022		)	107
Other income	95			72			220			91
Net income	$	6,639		$	6,554		$	30,191		$	22,984
Net income attributable to noncontrolling interests	(1		)	(20		)	(28		)	(77		)
Net income attributable to common unitholders	$	6,638		$	6,534		$	30,163		$	22,907
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.05		$	0.05		$	0.22		$	0.18
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.05		$	0.05		$	0.22		$	0.18
Weighted average common units outstanding:
Basic	143,137			128,793			138,314			127,781
Diluted	143,137			128,793			138,314			127,781
Dividends declared per common unit	$	0.300		$	0.295		$	0.890		$	0.875

The accompanying notes are an integral part of these condensed consolidated financial statements.

9

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS’ CAPITAL

(In thousands)

(Unaudited)

	General Partners’ Capital					Limited Partners’ Capital					Total Partners’ Capital
	Units		Amount			Units		Amount
Balance as of December 31, 2014	125,087		$	1,447,409		2,155		$	29,012		$	1,476,421
Issuance of general partner units	1,800		43,649			—		—			43,649
Share-based award transactions, net	200		4,462			(225	)	—			4,462
Redemption and cancellation of general partner units	(49	)	(1,322		)	—		—			(1,322		)
Distributions declared	—		(110,071		)	—		(1,695		)	(111,766		)
Net income	—		22,559			—		348			22,907
Balance as of September 30, 2015	127,038		$	1,406,686		1,930		$	27,665		$	1,434,351
Balance as of December 31, 2015	127,027		$	1,379,694		1,930		$	27,264		$	1,406,958
Issuance of general partner units, net	14,138		417,163			—		—			417,163
Issuance of limited partner units in connection with an acquisition	—		—			2,650		71,754			71,754
Share-based award transactions, net	393		5,136			—		—			5,136
Redemption and cancellation of general partner units	(87	)	(2,425		)	—		—			(2,425		)
Redemption of limited partner units and other	257		5,033			(257	)	(5,709		)	(676		)
Distributions declared	—		(121,686		)	—		(3,134		)	(124,820		)
Net income	—		29,361			—		802			30,163
Balance as of September 30, 2016	141,728		$	1,712,276		4,323		$	90,977		$	1,803,253

The accompanying notes are an integral part of these condensed consolidated financial statements.

10

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2016			2015
Cash flows from operating activities:
Net income	$	30,191		$	22,984
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	128,728			112,711
Share-based compensation expense	5,136			4,462
Bad debt expense	508			743
Gain on sale of real estate, net	(4,212		)	(152		)
Impairment	—			1,655
Loss (gain) on extinguishment of debt, net	3,022			(107		)
Change in fair value of derivative financial instruments	2,144			3,079
Changes in operating assets and liabilities:
Receivables and other assets, net	(14,051		)	(6,021		)
Accounts payable and accrued liabilities	3,598			(4,124		)
Prepaid rent and other liabilities	(6,807		)	3,429
Net cash provided by operating activities	148,257			138,659
Cash flows from investing activities:
Investments in real estate	(532,527		)	(253,107		)
Proceeds from the sale of real estate	23,368			33,279
Capital expenditures	(34,064		)	(17,330		)
Restricted cash, escrow deposits and other assets	2,143			2,994
Net cash used in investing activities	(541,080		)	(234,164		)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	513,000			387,000
Payments on unsecured revolving credit facility	(704,000		)	(247,000		)
Proceeds from unsecured senior notes	347,725			—
Borrowings on unsecured term loans	200,000			100,000
Payments on unsecured term loans	(155,000		)	—
Payments on secured mortgage loans	(98,453		)	(76,149		)
Deferred financing costs	(3,039		)	(289		)
Security deposits	862			145
Proceeds from issuance of general partner units	418,891			44,324
Repurchase and cancellation of general partner units	(2,425		)	(1,322		)
Distributions paid to general partner	(116,655		)	(108,891		)
Distributions paid to limited partners and redeemable noncontrolling interests	(2,724		)	(1,580		)
Redemption of redeemable noncontrolling interest	(491		)	—
Net cash provided by financing activities	397,691			96,238
Net change in cash and cash equivalents	4,868			733
Cash and cash equivalents - beginning of period	13,070			10,413
Cash and cash equivalents - end of period	$	17,938		$	11,146

The accompanying notes are an integral part of these condensed consolidated financial statements.

11

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Unless otherwise indicated or unless the context requires otherwise the use of the words “we,” “us” or “our” refers to Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP, collectively.

1. Organization and Description of Business

HTA, a Maryland corporation, and HTALP, a Delaware limited partnership, were incorporated or formed, as applicable, on April 20, 2006. HTA operates as a REIT and is the general partner of HTALP, which is the operating partnership. As of September 30, 2016, HTA owned a 97.0% partnership interest and other limited partners, including some of HTA’s directors, executive officers and their affiliates, owned the remaining partnership interest (including the LTIP units) in HTALP. As the sole general partner of HTALP, HTA has the full, exclusive and complete responsibility for HTALP’s day-to-day management and control. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP. As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP, issuing public equity from time to time and guaranteeing certain debts of HTALP. HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity.

HTA is one of the largest publicly-traded REITs focused on medical office buildings (“MOBs”) in the United States based on gross leasable area (“GLA”). HTA conducts substantially all of its operations through HTALP. We invest in MOBs that will serve the future of healthcare delivery, and these MOBs are primarily located on health system campuses, near university medical centers, or in core community outpatient locations. We also focus on our key markets that have certain demographic and macro-economic trends and where we can utilize our institutional property management and leasing platform to generate strong tenant relationships and operating cost efficiencies. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we: (i) seek internal growth through proactive asset management, leasing and property management oversight; (ii) target accretive acquisitions of MOBs in markets with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage. HTA has qualified to be taxed as a REIT for federal income tax purposes and intends to continue to be taxed as a REIT.

Since 2006, we have invested $4.2 billion to create a portfolio of MOBs and other healthcare assets consisting of approximately 17.6 million square feet of GLA throughout the U.S. As of September 30, 2016, approximately 97% of our portfolio, based on GLA, was located on the campuses of, or aligned with, nationally or regionally recognized healthcare systems. Our portfolio is diversified geographically across 31 states, with no state having more than 13% of our total GLA as of September 30, 2016. We are concentrated in 20 to 25 key markets that are experiencing higher economic and demographic trends, than other markets, on average, that we expect will drive demand for MOBs. Approximately 92% of our portfolio, based on GLA, is located in top 75 metropolitan statistical areas (“MSAs”) including concentrations in: Albany, Atlanta, Austin, Boston, Charleston, Columbus, Dallas, Denver, Greenville, Hartford/New Haven, Honolulu, Houston, Indianapolis, Miami, Orange County/Los Angeles, Orlando, Phoenix, Pittsburgh, Raleigh, Tampa and White Plains.

Our principal executive offices are located at 16435 North Scottsdale Road, Suite 320, Scottsdale, Arizona, 85254.

2. Summary of Significant Accounting Policies

The summary of significant accounting policies presented below is designed to assist in understanding our condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles (“GAAP”) in all material respects and have been consistently applied in preparing our accompanying condensed consolidated financial statements.

Basis of Presentation

Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

12

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2015 Annual Report on Form 10-K. There have been no significant changes to the Company’s significant accounting policies during the nine months ended September 30, 2016, except as noted below regarding the adoption of U.S. Financial Accounting Standards Board (the “FASB”) Accounting Standards Update (“ASU”) 2015-02, Amendments to the Consolidation Analysis and ASU 2015-16, Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments.

Principles of Consolidation

As of January 1, 2016, the Company adopted FASB ASU 2015-02, Amendments to the Consolidation Analysis, as described below in “Recently Issued or Adopted Accounting Pronouncements”, which simplifies consolidation accounting by reducing the number of consolidation models and changing various aspects of current GAAP, including certain consolidation criteria for VIEs. The consolidated financial statements include our accounts of those of our subsidiaries and consolidated joint venture arrangements. The portions of the operating partnership not owned by us are presented as non-controlling interests in our consolidated balance sheets and statements of operations, consolidated statements of equity, and consolidated statements of changes in partners’ capital. The portions of other joint venture arrangements not owned by us are presented as redeemable non-controlling interests in our consolidated balance sheets. In addition, as described in Note 1 - Organization and Description of Business, certain third parties have been issued limited partner units in HTALP (“OP Units”). Holders of OP Units are considered to be non-controlling interest holders in HTALP and their ownership interests are reflected as equity in the consolidated balance sheets. Further, a portion of the earnings and losses of HTALP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of common shares issued and the carrying value of the OP Units converted is recorded as a component of equity. As of September 30, 2016 and December 31, 2015, there were approximately 4.3 million and 1.9 million, respectively, of OP Units issued and outstanding.

VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. Our analysis of FASB ASU 2015-02 was concluded that our operating partnership and other joint venture arrangements are VIEs, as the limited partners in the related partnerships, although entitled to vote on certain matters, do not possess kick-out rights or substantive participating rights. Accordingly, we consolidate our interest in the operating partnership and other joint venture arrangements. Although, as we hold what is deemed a majority voting interest in the operating partnership and other joint venture arrangements, it qualifies for the exemption from providing certain of the disclosure requirements associated with investments in VIEs. We will evaluate on an ongoing basis the need to consolidate entities based on the standards set forth in GAAP as described above.

Investments in Real Estate

Depreciation expense of buildings and improvements for the three months ended September 30, 2016 and 2015 was $31.1 millionand $26.9 million, respectively. Depreciation expense of buildings and improvements for the nine months ended September 30, 2016 and 2015 was $86.6 million and $74.9 million, respectively.

13

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Recently Issued or Adopted Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. In July 2015, the FASB deferred the effective date of ASU 2014-09 to the first interim period within annual reporting periods beginning after December 15, 2017 along with the ability to early adopt as of the original effective date. We do not anticipate early adoption and we are evaluating the impact of adopting ASU 2014-09 on our consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis. ASU 2015-02 affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. The amendments in ASU 2015-02 affect the following areas: (i) limited partnerships and similar legal entities; (ii) evaluating fees paid to a decision maker or a service provider as a variable interest; (iii) the effect of fee arrangements on the primary beneficiary determination; (iv) the effect of related parties on the primary beneficiary determination; and (v) certain investment funds. ASU 2015-02 is effective for fiscal years and for interim periods within those fiscal years, beginning after December 15, 2015 with early adoption permitted. We adopted ASU 2015-02 as of January 1, 2016. The adoption had no material impact on our interests in joint venture arrangements. Accordingly, there was no material impact on previous or current reporting periods’ consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 changes the presentation of debt issuance costs by requiring these costs related to a recognized debt liability to be presented in the consolidated balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 to include the presentation and subsequent measurement of debt issuance costs associated with line-of-credit arrangements. ASU 2015-03 and 2015-15 are effective for the fiscal years beginning after December 15, 2015, and requires retrospective application with early adoption permitted. We adopted ASU 2015-03 and 2015-15 as of December 31, 2015. As a result of the adoption, all deferred financing costs, excluding costs related to the unsecured revolving credit facility, were reclassed to debt. Unsecured revolving credit facility costs remain classified as an asset on our consolidated balance sheets and will continue to be amortized over the remaining term. The guidance requires retrospective adoption for all prior periods presented.

In September 2015, the FASB issued ASU 2015-16, Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments. ASU 2015-16 eliminates the requirement that an acquirer in a business combination has to account for measurement-period adjustments retrospectively. Instead, acquirers must recognize measurement-period adjustments during the period in which they determine the amount of the adjustment, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. ASU 2015-16 is effective for fiscal years beginning after December 15, 2015. We adopted ASU 2015-16 as of January 1, 2016. As a result of the adoption there was no material impact in the previous or current reporting periods’ consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases. ASU 2016-02 will supersede the existing guidance for lease accounting and states that companies will be required to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 requires qualitative and quantitative disclosures to supplement the amounts recorded in the financial statements so that users can understand the nature of the entity’s leasing activities, including significant judgments and changes in judgments. Within ASU 2016-02 lessor accounting remained fairly unchanged. In adopting ASU 2016-02, companies will be required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. ASU 2016-02 is effective for the fiscal years beginning after December 15, 2018 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-02 on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Compensation Accounting. ASU 2016-09 includes multiple provisions intended to simplify various aspects of accounting for share-based compensation which includes, but is not limited to, the requirement that excess tax benefits be recorded within the income statement as opposed to additional paid-in-capital and treated as an operating activity within the statement of cash flows. In addition, ASU 2016-09 allows companies to make an accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-09 on our consolidated financial statements.

14

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). ASU 2016-13 is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2016-13 is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 includes multiple provisions intended to clarify various aspects of cash flow presentation by making eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-15 on our consolidated financial statements.

3. Investments in Real Estate

For the nine months ended September 30, 2016, our investments had an aggregate purchase price of $633.0 million. We incurred $2.5 million of costs attributable to these investments, which were recorded in acquisition-related expenses in the accompanying condensed consolidated statements of operations. As part of the acquisitions, we assumed mortgage loans with an aggregate fair value of $20.0 million and issued 2,650,409 OP Units with a market value at the time of issuance of $71.8 million.

The following investments were determined to be individually not significant, but significant on a collective basis. The actual revenues and earnings since the investment dates as well as the supplementary proforma information assuming these investments occurred as of the beginning of the prior periods, were not material to us. The purchase price allocation for each of our investments are preliminary and subject to change until allocations are finalized, which will be no later than 12 months from the date of acquisition. The preliminary allocations for these investments are set forth below in the aggregate for the nine months ended September 30, 2016 and 2015 (in thousands):

	Nine Months Ended September 30,
	2016			2015
Land	$	77,949		$	13,286
Building and improvements	505,138			229,386
In place leases	50,997			22,414
Below market leases	(12,790		)	(8,206		)
Above market leases	4,413			1,254
Below market leasehold interests	4,188			2,698
Above market leasehold interests	(50		)	(7,725		)
Below market debt	360			—
Interest rate swaps	(779		)	—
Net assets acquired	629,426			253,107
Other, net	3,540			1,503
Aggregate purchase price	$	632,966		$	254,610

The acquired intangible assets and liabilities referenced above had weighted average lives of the following for the nine months ended September 30, 2016 and 2015 (in years):

	Nine Months Ended September 30,
	2016	2015
Acquired intangible assets	9.1	26.8
Acquired intangible liabilities	8.3	52.4

15

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Subsequent to September 30, 2016, we completed an investment with a purchase price of $7.2 million. The purchase price of this building was subject to certain post-closing adjustments. Due to the recent timing of the acquisition of this investment, we have not completed our initial purchase price allocation with respect to this investment and, therefore, cannot provide disclosures at this time similar to those contained in Note 3 - Investments in Real Estate to our condensed consolidated financial statements.

4. Dispositions

During the nine months ended September 30, 2016, we completed a disposition of four senior care facilities for an aggregate gross sales price of $26.5 million, generating a gain of $4.2 million.

5. Intangible Assets and Liabilities

Intangible assets and liabilities consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands, except weighted average remaining amortization):

	September 30, 2016				December 31, 2015
	Balance			Weighted Average Remaining Amortization in Years	Balance			Weighted Average Remaining Amortization in Years
Assets:
In place leases	$	291,851		9.9	$	249,824		11.0
Tenant relationships	174,583			10.5	180,925			10.4
Above market leases	28,306			6.4	24,974			6.0
Below market leasehold interests	38,795			60.4	34,606			63.0
	533,535				490,329
Accumulated amortization	(246,868		)		(219,334		)
Total	$	286,667		16.1	$	270,995		16.6
Liabilities:
Below market leases	$	34,125		19.1	$	22,240		27.2
Above market leasehold interests	11,632			53.2	11,582			53.7
	45,757				33,822
Accumulated amortization	(8,829		)		(7,211		)
Total	$	36,928		29.0	$	26,611		38.0

The following is a summary of the net intangible amortization for the three and nine months ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2016			2015		2016		2015
Amortization recorded against rental income related to above or (below) market leases	$	(115	)	$	509	$	202	$	1,428
Rental expense related to above or (below) market leasehold interests	118			94		321		327
Amortization expense related to in place leases and tenant relationships	15,266			12,266		39,483		36,371

16

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

6. Receivables and Other Assets

Receivables and other assets consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands):

	September 30, 2016		December 31, 2015
Tenant receivables, net	$	8,940	$	5,820
Other receivables, net	11,311		11,882
Deferred financing costs, net	4,529		5,524
Deferred leasing costs, net	19,690		17,923
Straight-line rent receivables, net	72,354		65,543
Prepaid expenses, deposits, equipment and other, net	44,013		34,584
Derivative financial instruments - interest rate swaps	—		427
Total	$	160,837	$	141,703

The following is a summary of the amortization of deferred leasing costs and financing costs for the three and nine months ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Amortization expense related to deferred leasing costs	$	1,224	$	1,013	$	3,368	$	2,941
Interest expense related to deferred financing costs (1)	331		320		994		985
(1) For the three and nine months ended September 30, 2015, amounts have been adjusted to reflect the retrospective presentation of the early adoption of ASU 2015-03 and 2015-15 as of December 31, 2015.

7. Debt

Debt consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands):

	September 30, 2016			December 31, 2015
Unsecured revolving credit facility	$	27,000		$	218,000
Unsecured term loans	500,000			455,000
Unsecured senior notes	950,000			600,000
Fixed rate mortgages loans	209,797			298,030
Variable rate mortgages loans	39,140			28,988
	1,725,937			1,600,018
Deferred financing costs, net	(9,853		)	(8,411		)
Discount, net	(3,486		)	(911		)
Total	$	1,712,598		$	1,590,696

Unsecured Credit Agreement

Unsecured Revolving Credit Facility

On February 11, 2015, we executed an amendment to the unsecured revolving credit and term loan facility (the “Unsecured Credit Agreement”) which increased the amount available under the unsecured revolving credit facility to $850.0 million. The actual amount of credit available to us is a function of certain loan-to-value and debt service coverage ratios set forth in the unsecured revolving credit facility. The maximum principal amount of the unsecured revolving credit facility may be increased, subject to additional financing being provided by our existing lenders or new lenders being added to the unsecured revolving credit facility. The unsecured revolving credit facility matures on January 31, 2020 and is guaranteed by HTA.

Borrowings under the unsecured revolving credit facility accrue interest at a rate equal to adjusted LIBOR, plus a margin ranging from 0.88% to 1.55% per annum based on our credit rating. We also pay a facility fee ranging from 0.13% to 0.30% per annum on the aggregate commitments under the unsecured revolving credit facility. As of September 30, 2016, the margin associated with our borrowings was 1.05% per annum and the facility fee was 0.20% per annum.

17

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Unsecured Term Loan

As of September 30, 2016, we had a $300.0 million unsecured term loan outstanding that was guaranteed by HTA. Borrowings accrue interest at a rate equal to adjusted LIBOR, plus a margin ranging from 0.90% to 1.80% per annum based on our credit rating. The margin associated with our borrowings as of September 30, 2016 was 1.15% per annum. Including the impact of the interest rate swaps associated with our unsecured term loan, the interest rate was 1.65% per annum, based on our current credit rating. The unsecured term loan matures on January 31, 2019, and includes a one-year extension exercisable at the option of the borrower, subject to certain conditions.

$200.0 Million Unsecured Term Loan

On September 26, 2016, HTALP executed a $200.0 million unsecured term loan due on September 26, 2023. Proceeds were used to refinance our $155.0 million unsecured term loan due on July 19, 2019 and pay down existing mortgage loans. Borrowings under the unsecured term loan accrue interest at a rate equal to LIBOR, plus a margin ranging from 1.50% to 2.45% per annum based on our credit rating. The margin associated with our borrowings as of September 30, 2016 was 1.65% per annum. HTALP had interest rate swaps in place that fix the interest rate at 2.76% per annum, based on our current credit rating. As of September 30, 2016, HTALP had a $200.0 million unsecured term loan outstanding.

$300.0 Million Unsecured Senior Notes due 2021

As of September 30, 2016, HTALP had $300.0 million of unsecured senior notes outstanding that are guaranteed by HTA and that mature on July 15, 2021. The unsecured senior notes are registered under the Securities Act of 1933, as amended (the “Securities Act”), bear interest at 3.38% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.21% of the principal amount thereof, with an effective yield to maturity of 3.50% per annum.

$300.0 Million Unsecured Senior Notes due 2023

As of September 30, 2016, HTALP had $300.0 million of unsecured senior notes outstanding that are guaranteed by HTA and that mature on April 15, 2023. The unsecured senior notes are registered under the Securities Act, bear interest at 3.70% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.19% of the principal amount thereof, with an effective yield to maturity of 3.80% per annum.

$350.0 million Unsecured Senior Notes due 2026

On July 12, 2016, HTALP executed $350.0 million unsecured senior notes that are guaranteed by HTA. The unsecured senior notes are registered under the Securities Act, bear interest at 3.50% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.72% of the principal amount thereof, with an effective yield to maturity of 3.53% per annum. As of September 30, 2016, HTALP had $350.0 million of unsecured senior notes outstanding that mature on August 1, 2026.

Fixed and Variable Rate Mortgages Loans

As of September 30, 2016, HTALP and its subsidiaries had fixed and variable rate mortgages loans with interest rates ranging from 1.95% to 6.26% per annum and a weighted average interest rate of 5.03% per annum. Including the impact of the interest rate swap associated with our variable rate mortgage loans, the weighted average interest rate was 5.43% per annum.

Future Debt Maturities

The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of September 30, 2016 (in thousands):

Year	Amount
2016	$	1,433
2017	87,268
2018	4,333
2019	304,580
2020	76,796
Thereafter	1,251,527
Total	$	1,725,937

The above scheduled debt maturities do not include the extension available to us under the Unsecured Credit Agreement as discussed above.

18

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Deferred Financing Costs

As of September 30, 2016, the future amortization of deferred financing costs is as follows (in thousands):

Year	Amount
2016	$	481
2017	1,829
2018	1,757
2019	1,762
2020	1,320
Thereafter	2,704
Total	$	9,853

We are required by the terms of our applicable debt agreements to meet various affirmative and negative covenants that we believe are customary for these types of facilities, such as limitations on the incurrence of debt by us and our subsidiaries that own unencumbered assets, limitations on the nature of HTALP’s business, and limitations on distributions by HTALP and its subsidiaries that own unencumbered assets. Our debt agreements also impose various financial covenants on us, such as a maximum ratio of total indebtedness to total asset value, a minimum ratio of EBITDA to fixed charges, a minimum tangible net worth covenant, a maximum ratio of unsecured indebtedness to unencumbered asset value, rent coverage ratios and a minimum ratio of unencumbered net operating income to unsecured interest expense. As of September 30, 2016, we believe that we were in compliance with all such financial covenants and reporting requirements. In addition, certain of our debt agreements include events of default provisions that we believe are customary for these types of facilities, including restricting HTA from making dividend distributions to its stockholders in the event HTA is in default thereunder, except to the extent necessary for HTA to maintain its REIT status.

8. Derivative Financial Instruments

The following table lists the derivative financial instrument assets and (liabilities) held by us as of September 30, 2016 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	50,000	LIBOR	1.39	%	$	(729	)	Swap	7/17/2019
105,000		LIBOR	1.24		(1,073		)	Swap	7/17/2019
25,480		LIBOR + 1.45%	4.98		(2,224		)	Swap	5/1/2020
6,135		LIBOR + 2.25%	4.04		(243		)	Swap	1/1/2023
4,406		LIBOR + 0.49%	3.52		(597		)	Swap	12/1/2023

The following table lists the derivative financial instrument assets and (liabilities) held by us as of December 31, 2015 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	100,000	LIBOR	0.86	%	$	(142	)	Swap	6/15/2016
50,000		LIBOR	1.39		(71		)	Swap	7/17/2019
105,000		LIBOR	1.24		427			Swap	7/17/2019
26,092		LIBOR + 1.45%	4.98		(2,157		)	Swap	5/1/2020

As of September 30, 2016 and December 31, 2015, the gross fair value of our derivative financial instruments was as follows (in thousands):

	Asset Derivatives					Liability Derivatives
		Fair Value					Fair Value
Derivatives Not Designated as Hedging Instruments:	Balance Sheet Location	September 30, 2016		December 31, 2015		Balance Sheet Location	September 30, 2016		December 31, 2015
Interest rate swaps	Receivables and other assets	$	—	$	427	Derivative financial instruments	$	4,866	$	2,370

19

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

There were no derivatives offset in our accompanying condensed consolidated balance sheets as of September 30, 2016 and December 31, 2015. As of September 30, 2016 and December 31, 2015, we had derivatives subject to enforceable master netting arrangements which allowed for net cash settlement with the respective counterparties (in thousands):

	September 30, 2016						December 31, 2015
	Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements		Net Amounts		Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements			Net Amounts
Asset derivatives	$	—	$	—	$	—	$	427	$	(427	)	$	—
Liability derivatives	4,866		—		4,866		2,370		(427		)	1,943

We have agreements with each of our interest rate swap derivative counterparties which provide that if we default on certain of our unsecured indebtedness, our counterparties could declare us in default on our interest rate swap derivative obligations resulting in an acceleration of the indebtedness. In addition, we are exposed to credit risk in the event of non-performance by our derivative counterparties. We believe we mitigate the credit risk by entering into agreements with credit-worthy counterparties. We record counterparty credit risk valuation adjustments on interest rate swap derivative assets in order to properly reflect the credit quality of the counterparty. In addition, our fair value of interest rate swap derivative liabilities is adjusted to reflect the impact of our credit quality. As of September 30, 2016, there have been no termination events or events of default related to our interest rate swaps.

9. Commitments and Contingencies

Litigation

We are not presently subject to any material litigation nor, to our knowledge, is any material litigation threatened against us, which if determined unfavorably to us, would have a material effect on our condensed consolidated financial position, results of operations or cash flows.

Environmental Matters

We follow the policy of monitoring our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our condensed consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability at our properties that we believe would require additional disclosure or the recording of a loss contingency.

Other

Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business. In our opinion, these matters are not expected to have a material effect on our condensed consolidated financial position, results of operations or cash flows.

10. Stockholders’ Equity and Partners’ Capital

HTALP’s partnership agreement provides that it will distribute cash flow from operations and net sale proceeds to its partners in accordance with their overall ownership interests at such times and in such amounts as the general partner determines. Dividend distributions are made such that a holder of one partnership unit in HTALP will receive distributions from HTALP in an amount equal to the dividend distributions paid to the holder of one share of HTA’s common stock. In addition, for each share of common stock issued or redeemed by HTA, HTALP issues or redeems a corresponding number of partnership units.

20

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

During the nine months ended September 30, 2016, HTA issued $492.5 million of equity at an average price of $29.33 per share.

Common Stock Offerings

In January 2016, HTA entered into a new equity distribution agreement with respect to its at-the-market (“ATM”) offering program of common stock with an aggregate sales amount of up to $300.0 million. During the nine months ended September 30, 2016, HTA issued and sold 4,418,571 shares of its common stock for $122.9 million at an average price of $27.82 per share, and as of September 30, 2016, $177.1 million remained available for issuance under the ATM.

During the nine months ended September 30, 2016, HTA completed underwritten public offerings with a cumulative 9,720,000 shares of common stock for $297.8 million at an average price of $30.64 per share.

Common Unit Offerings

During the nine months ended September 30, 2016, HTA issued 2,650,409 OP Units in HTALP, respectively, for approximately $71.8 million in connection with acquisition transactions.

Common Stock Dividends

See our accompanying condensed consolidated statements of operations for the dividends declared during the three and nine months ended September 30, 2016 and 2015. On October 25, 2016, HTA declared a quarterly cash dividend of $0.30 per share to be paid on January 10, 2017 to stockholders of record of its common stock on January 3, 2017.

Incentive Plan

HTA’s Amended and Restated 2006 Incentive Plan (the “Plan”) permits the grant of incentive awards to our employees, officers, non-employee directors and consultants as selected by our Board of Directors. The Plan authorizes the granting of awards in any of the following forms: options; stock appreciation rights; restricted stock; restricted or deferred stock units; performance awards; dividend equivalents; other stock-based awards, including units in HTALP; and cash-based awards. Subject to adjustment as provided in the Plan, the aggregate number of awards reserved and available for issuance under the Plan is 5,000,000. As of September 30, 2016, there were 1,921,610 awards available for grant under the Plan.

LTIP Units

Awards under the LTIP consist of Series C units inHTALPand were subject to the achievement of certain performance and market conditions in order to vest. Once vested, the Series C units were converted into common units of HTALP, which may be converted into shares of HTA’s common stock. The LTIP awards were fully expensed in 2013, except for225,000units that were forfeited in 2015.

Restricted Common Stock

For the three and nine months ended September 30, 2016, we recognized compensation expense of $2.1 million and $5.1 million, respectively. For the three and nine months ended September 30, 2015, we recognized compensation expense of $1.4 million and $4.5 million, respectively. Compensation expense for the three and nine months ended September 30, 2016 and 2015 were recorded in general and administrative expenses in the accompanying condensed consolidated statements of operations.

As of September 30, 2016, there was $10.2 million of unrecognized compensation expense net of estimated forfeitures, which will be recognized over a remaining weighted average period of 2.0 years.

The following is a summary of our restricted common stock activity during the nine months ended September 30, 2016 and 2015 (in thousands, except weighted average grant date fair value):

	September 30, 2016				September 30, 2015
	Restricted Common Stock		Weighted Average Grant Date Fair Value		Restricted Common Stock		Weighted Average Grant Date Fair Value
Beginning balance	487,850		$	23.13	463,050		$	20.90
Granted	417,110		29.82		221,076		26.57
Vested	(236,749	)	23.27		(135,213	)	21.89
Forfeited	(24,391	)	25.93		(21,378	)	22.70
Ending balance	643,820		$	27.35	527,535		$	22.88

21

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

11. Fair Value of Financial Instruments

Financial Instruments Reported at Fair Value - Recurring

The table below presents our assets and liabilities measured at fair value on a recurring basis as of September 30, 2016, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	—	$	—	$	—
Liabilities:
Derivative financial instruments	$	—	$	4,866	$	—	$	4,866

The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2015, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	427	$	—	$	427
Liabilities:
Derivative financial instruments	$	—	$	2,370	$	—	$	2,370

Financial Instruments Reported at Fair Value - Non-Recurring

As of September 30, 2016, there were noassets measured at fair value on a non-recurring basis. The table below presents our assets measured at fair value on a non-recurring basis as of December 31, 2015, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
MOB (1)	$	—	$	547	$	—	$	547
(1) During the year ended December 31, 2015, we recognized a $0.9 million impairment charge to the carrying value of an MOB. The estimated fair value as of December 31, 2015 was based upon a pending sales agreement pertaining to this MOB.

There have been no transfers of assets or liabilities between levels. We will record any such transfers at the end of the reporting period in which a change of event occurs that results in a transfer. Although we have determined that the majority of the inputs used to value our interest rate swap derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. However, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our interest rate swap derivative positions and have determined that the credit valuation adjustments are not significant to their overall valuation. As a result, we have determined that our interest rate swap derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Financial Instruments Disclosed at Fair Value

We consider the carrying values of cash and cash equivalents, tenant and other receivables, restricted cash and escrow deposits and accounts payable, and accrued liabilities, to approximate fair value for these financial instruments because of the short period of time between origination of the instruments and their expected realization. All of these financial instruments are considered Level 2.

The fair value of debt is estimated using borrowing rates available to us with similar terms and maturities, which is considered a Level 2 input. As of September 30, 2016, the fair value of the debt was $1,781.6 million compared to the carrying value of $1,712.6 million. As of December 31, 2015, the fair value of the debt was $1,619.7 million compared to the carrying value of $1,590.7 million.

22

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

12. Per Share Data of HTA

HTA includes unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents as “participating securities” pursuant to the two-class method. The resulting classes are our common stock and restricted stock. For the three and nine months ended September 30, 2016 and 2015, all of HTA’s earnings were distributed and the calculated earnings per share amount would be the same for all classes.

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three and nine months ended September 30, 2016 and 2015 (in thousands, except per share data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Numerator:
Net income	$	6,639		$	6,554		$	30,191		$	22,984
Net income attributable to noncontrolling interests	(212		)	(91		)	(830		)	(425		)
Net income attributable to common stockholders	$	6,427		$	6,463		$	29,361		$	22,559
Denominator:
Weighted average shares outstanding - basic	138,807			126,863			134,905			125,750
Dilutive shares	4,331			1,930			3,409			1,930
Weighted average shares outstanding - diluted	143,138			128,793			138,314			127,680
Earnings per common share - basic
Net income attributable to common stockholders	$	0.05		$	0.05		$	0.22		$	0.18
Earnings per common share - diluted
Net income attributable to common stockholders	$	0.04		$	0.05		$	0.21		$	0.18

13. Per Unit Data of HTALP

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and nine months ended September 30, 2016 and 2015 (in thousands, except per unit data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Numerator:
Net income	$	6,639		$	6,554		$	30,191		$	22,984
Net income attributable to noncontrolling interests	(1		)	(20		)	(28		)	(77		)
Net income attributable to common unitholders	$	6,638		$	6,534		$	30,163		$	22,907
Denominator:
Weighted average units outstanding - basic	143,137			128,793			138,314			127,781
Dilutive units	—			—			—			—
Weighted average units outstanding - diluted	143,137			128,793			138,314			127,781
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.05		$	0.05		$	0.22		$	0.18
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.05		$	0.05		$	0.22		$	0.18

23

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

14. Supplemental Cash Flow Information

The following is the supplemental cash flow information for the nine months ended September 30, 2016 and 2015 (in thousands):

	Nine Months Ended September 30,
	2016		2015
Supplemental Disclosure of Cash Flow Information:
Interest paid	$	39,321	$	39,570
Income taxes paid	934		790
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accrued capital expenditures	$	2,868	$	1,833
Debt and interest rate swaps assumed in connection with an acquisition	21,156		—
Dividend distributions declared, but not paid	43,530		37,712
Issuance of operating partnership units in connection with an acquisition	71,754		—
Note receivable included in the consideration of a disposition	3,000		—
Redeemable noncontrolling interest assumed in connection with an acquisition	5,449		—
Redemption of noncontrolling interests	5,709		—

24

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The use of the words “we,” “us” or “our” refers to HTA and HTALP, collectively.

The following discussion should be read in conjunction with our condensed consolidated financial statements and notes appearing elsewhere in this Quarterly Report, as well as with the audited consolidated financial statements, accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2015 Annual Report on Form 10-K. Such condensed consolidated financial statements and information have been prepared to reflect HTA’s and HTALP’s financial position as of September 30, 2016 and December 31, 2015, together with results of operations and cash flows for the three and nine months ended September 30, 2016 and 2015.

The information set forth below is intended to provide readers with an understanding of our financial condition, changes in financial condition and results of operations.

• Forward-Looking Statements;

• Executive Summary;

• Company Highlights;

• Critical Accounting Policies;

• Recently Issued or Adopted Accounting Pronouncements;

• Factors Which May Influence Results of Operations;

• Results of Operations;

• Non-GAAP Financial Measures;

• Liquidity and Capital Resources;

• Commitments and Contingencies;

• Debt Service Requirements;

• Off-Balance Sheet Arrangements; and

• Inflation.

Forward-Looking Statements

Certain statements contained in this Quarterly Report constitute forward-looking statements within the meaning of the safe harbor from civil liability provided for such statements by the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”)). Such statements include, in particular, statements about our plans, strategies, prospects and estimates regarding future MOB market performance. Additionally, such statements are subject to certain risks and uncertainties, as well as known and unknown risks, which could cause actual results to differ materially and in adverse ways from those projected or anticipated. Therefore, such statements are not intended to be a guarantee of our performance in future periods. Forward-looking statements are generally identifiable by the use of such terms as “expect,” “project,” “may,” “should,” “could,” “would,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “opinion,” “predict,” “potential,” “pro forma” or the negative of such terms and other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this Quarterly Report is filed with the SEC. We cannot guarantee the accuracy of any such forward-looking statements contained in this Quarterly Report, and we do not intend to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Any such forward-looking statements reflect our current views about future events, are subject to unknown risks, uncertainties, and other factors, and are based on a number of assumptions involving judgments with respect to, among other things, future economic, competitive and market conditions, all of which are difficult or impossible to predict accurately. To the extent that our assumptions differ from actual results, our ability to meet such forward-looking statements, including our ability to generate positive cash flow from operations, provide dividends to stockholders and maintain the value of our real estate properties, may be significantly hindered. Factors that might impair our ability to meet such forward-looking statements include, without limitation, those discussed in Part I, Item 1A - Risk Factors in our 2015 Annual Report on Form 10-K, which is incorporated herein.

25

Forward-looking statements express expectations of future events. All forward-looking statements are inherently uncertain as they are based on various expectations and assumptions concerning future events and they are subject to numerous known and unknown risks and uncertainties that could cause actual events or results to differ materially from those projected. Due to these inherent uncertainties, our stockholders are urged not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date made. In addition, we undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to projections over time, except as required by law.

These risks and uncertainties should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. Additional information concerning us and our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Executive Summary

HTA is one of the largest publicly-traded REITs focused on MOBs in the U.S. based on the GLA of its MOBs. HTA conducts substantially all of its operations through HTALP. We invest in MOBs that will serve the future of healthcare delivery, and these MOBs are primarily located on health system campuses, near university medical centers, or in core community outpatient locations. We also focus on our key markets that have certain demographic and macro-economic trends and where we can utilize our institutional property management and leasing platform to generate strong tenant relationships and operating cost efficiencies. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we: (i) seek internal growth through proactive asset management, leasing and property management oversight; (ii) target accretive acquisitions of MOBs in markets with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage.

Since 2006, we have invested $4.2 billion to create a portfolio of MOBs and other healthcare assets consisting of approximately 17.6 million square feet of GLA throughout the U.S. As of September 30, 2016, approximately 97% of our portfolio, based on GLA, was located on the campuses of, or aligned with, nationally or regionally recognized healthcare systems. Our portfolio is diversified geographically across 31 states, with no state having more than 13% of our total GLA as of September 30, 2016. We are concentrated in 20 to 25 key markets that are experiencing higher economic and demographic trends, than other markets, on average, that we expect will drive demand for MOBs. Approximately 92% of our portfolio, based on GLA, is located in top 75 MSAs including concentrations in: Albany, Atlanta, Austin, Boston, Charleston, Columbus, Dallas, Denver, Greenville, Hartford/New Haven, Honolulu, Houston, Indianapolis, Miami, Orange County/Los Angeles, Orlando, Phoenix, Pittsburgh, Raleigh, Tampa and White Plains.

Company Highlights

Portfolio Operating Performance

• For the three months ended September 30, 2016, our total revenue increased13.9%, or $14.4 million, to $118.3 million, compared to the three months ended September 30, 2015. For the nine months ended September 30, 2016, our total revenue increased12.3%, or $37.1 million, to $338.9 million, compared to the nine months ended September 30, 2015.

• For the three months ended September 30, 2016, net income attributable to common stockholders was$0.04per diluted share, or$6.4 million, compared to$0.05per diluted share, or$6.5 million, for thethree months ended September 30, 2015. FFO, as noted below, increased due to the continued growth in our operations, however, net income was adversely affected by the payment of debt extinguishment costs and interest related to debt. For thenine months ended September 30, 2016, net income attributable to common stockholders was $0.21 per diluted share, or $29.4 million, compared to $0.18 per diluted share, or $22.6 million, for the nine months ended September 30, 2015.

• For the three months ended September 30, 2016, HTA’s FFO was $0.38 per diluted share, or $54.0 million, an increase of $0.02 per diluted share, or 5.6%, compared to the three months ended September 30, 2015. For the nine months ended September 30, 2016, HTA’s FFO was $1.12 per diluted share, or $154.6 million, an increase of $0.04 per diluted share, or 3.7%, compared to the nine months ended September 30, 2015.

• For the three months ended September 30, 2016, HTA’s Normalized FFO was $0.40 per diluted share, or $57.1 million, an increase of $0.01 per diluted share, or 2.6%, compared to the three months ended September 30, 2015. For the nine months ended September 30, 2016, HTA’s Normalized FFO was $1.20 per diluted share, or $165.7 million, an increase of $0.06 per diluted share, or 5.3%, compared to the nine months ended September 30, 2015.

• For additional information on FFO and Normalized FFO, see “FFO and Normalized FFO” below, which includes a reconciliation to net income attributable to common stockholders/unitholders and an explanation of why we present this non-GAAP financial measure.

26

• For the three months ended September 30, 2016, our Net Operating Income (“NOI”) increased14.7%, or $10.4 million, to $81.5 million, compared to the three months ended September 30, 2015. For the nine months ended September 30, 2016, our NOI increased11.8%, or $24.7 million, to $233.6 million, compared to the nine months ended September 30, 2015.

• For the three months ended September 30, 2016, our Same-Property Cash NOI increased3.3%, or $2.2 million, to $68.6 million, compared to the three months ended September 30, 2015. For the nine months ended September 30, 2016, our Same-Property Cash NOI increased3.0%, or $5.6 million, to $192.8 million, compared to the nine months ended September 30, 2015.

• For additional information on NOI and Same-Property Cash NOI, see “NOI, Cash NOI and Same-Property Cash NOI” below, which includes a reconciliation from net income and an explanation of why we present these non-GAAP financial measures.

Internal Growth through Proactive Asset Management Leasing and Property Management

• As of September 30, 2016, our leased rate (includes leases which have been executed, but which have not yet commenced) was 91.8% by GLA and our occupancy rate was 91.3% by GLA.

• We entered into new and renewal leases on approximately 339,000 and 1.1 million square feet of GLA, or 1.9% and 6.4% of our portfolio, during the three and nine months ended September 30, 2016, respectively.

• Tenant retention for the Same-Property portfolio was 67% and 79%, which included approximately 309,000 and 932,000 square feet of expiring leases, for the quarter and year to date, respectively, which we believe is indicative of our commitment to maintaining buildings in desirable locations and fostering strong tenant relationships. Tenant retention for the Same-Property portfolio, excluding the impact of the Forest Park Medical Center hospital leases, was 84% by GLA for the quarter and year to date. Tenant retention is defined as the sum of the total leased GLA of tenants that renewed a lease during the period over the total GLA of leases that renewed or expired during the period.

• As of September 30, 2016, our in-house property management and leasing platform operated approximately 16.0 million square feet of GLA, or 91% of our total portfolio.

Key Market Focused Strategy and Investments

We believe we have been one of the most active investors in the medical office sector over the last ten years and have developed a strong presence across 20 to 25 key markets. In each of these markets we have established a strong asset management and leasing platform that has allowed us to develop valuable relationships with health systems, physician practices, universities, and regional development firms that have led to investment and leasing opportunities. Our local platforms have also enabled us to focus on generating cost efficiencies as we gain scale across individual markets and regions.

• As of September 30, 2016, we had over 700,000 square feet of GLA in each of our top ten markets. We expect to establish this scale across 20 to 25 key markets as our portfolio expands.

• Our key markets represent top MSAs with strong growth metrics in jobs and population, low unemployment and mature healthcare infrastructures.

• Our investment strategy includes the alignment with key healthcare systems, hospitals and leading academic medical universities.

• Over the last several years, our investments have been focused in our key markets, with the majority of our investments also being located either on the campuses of, or aligned with, nationally and regionally recognized healthcare systems.

• During the nine months ended September 30, 2016, we acquired investments totaling $633.0 million located in our key markets of Columbus, Ohio; Dallas, Texas; Hartford, Connecticut; and Tampa, Florida, and strategically expanded our presence into three new markets of Birmingham, Alabama; Orange County/Los Angeles, California; and Portland, Oregon.

• During the nine months ended September 30, 2016, we completed the disposition of four senior care facilities located in Texas for an aggregate gross sales price of $26.5 million, generating a gain of$4.2 million.

Financial Strategy and Balance Sheet Flexibility

• As of September 30, 2016, we had total leverage of 26.4% measured as debt to capitalization. Total liquidity was $835.4 million, including cash and cash equivalents of $17.9 million and $817.5 million available on our unsecured revolving credit facility (includes the impact of $5.5 million of outstanding letters of credit) as of September 30, 2016.

27

• During the nine months ended September 30, 2016, we issued $492.5 million of equity comprised of $297.8 million from the sale of common stock in an underwritten public offering at an average price of $30.64 per share, $122.9 million from the sale of common stock under the ATM at an average price of $27.82 per share, and $71.8 million from the issuance of OP Units in connection with acquisition transactions.

• In July 2016, HTALP issued $350.0 million of senior unsecured 10-year notes, with a coupon of 3.50% per annum.

• In September 2016, HTALP executed a $200.0 million 7-year unsecured term loan with proceeds used to refinance our $155.0 million unsecured term loan due in 2019 and pay down existing mortgage loans.

Critical Accounting Policies

The complete list of our critical accounting policies was disclosed in our 2015 Annual Report on Form 10-K. There have been no material changes to our critical accounting policies as disclosed herein.

Recently Issued or Adopted Accounting Pronouncements

See Note 2 - Summary of Significant Accounting Policies to our accompanying condensed consolidated financial statements for a discussion of recently issued or adopted accounting pronouncements.

Factors Which May Influence Results of Operations

We are not aware of any material trends or uncertainties, other than national economic conditions affecting real estate generally and the risk factors previously listed in Part I, Item 1A - Risk Factors, in our 2015 Annual Report on Form 10-K that may reasonably be expected to have a material impact, favorable or unfavorable, on revenues or income from the investment, management and operation of our properties.

Rental Income

The amount of rental income generated by our properties depends principally on our ability to maintain the occupancy rates of currently leased space and to lease currently available space and space that will become available from unscheduled lease terminations at the then applicable rental rates. Negative trends in one or more of these factors could adversely affect our rental income in future periods.

Investment Activity

During the nine months ended September 30, 2016, we had investments with an aggregate purchase price of $633.0 million and a disposition with a gross sales price of $26.5 million. During the nine months ended September 30, 2015, we had investments with an aggregate purchase price of $254.6 million and dispositions with an aggregate gross sales price of $35.7 million. The amount of any future acquisitions or dispositions could have a significant impact on our results of operations in future periods.

Results of Operations

Comparison of the Three and Nine Months Ended September 30, 2016 and 2015

As of September 30, 2016, we owned and operated approximately 17.6 million square feet of GLA, with a 91.8% leased rate (includes leases which have been executed, but which have not yet commenced) and a 91.3% occupancy rate. As of September 30, 2015, we owned and operated approximately 15.3 million square feet of GLA, with a 92.0% leased rate (includes leases which have been executed, but which have not yet commenced) and a 91.2% occupancy rate. All explanations are applicable to both HTA and HTALP unless otherwise noted.

Rental Income

For the three and nine months ended September 30, 2016 and 2015, rental income was comprised of the following (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Contractual rental income	$	114,202	$	100,385	$	327,779	$	291,667
Straight-line rent and amortization of above/below market leases	2,299		2,319		6,503		6,535
Other operating revenue	1,751		1,171		4,364		3,368
Total	$	118,252	$	103,875	$	338,646	$	301,570

28

Contractual rental income, which includes expense reimbursements, increased$13.8 million and $36.1 million for the three and nine months ended September 30, 2016, respectively, compared to the three and nine months ended September 30, 2015. These increases were primarily due to $15.3 million and $39.5 million of additional contractual rental income from our 2015 and 2016 acquisitions (including properties owned in both periods) and contractual rent increases, partially offset by a decrease in contractual rent as a result of buildings we sold during 2015 and 2016 for the three and nine months ended September 30, 2016, respectively.

Average starting and ending annual base rents and square feet entered into for new and renewal leases consist of the following for the three and nine months ended September 30, 2016 and 2015 (in square feet and per square foot of GLA):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
New and Renewal leases:
Average starting annual base rents	$	25.17	$	24.20	$	22.67	$	23.16
Average ending annual base rents	24.60		24.02		22.54		23.07
Square feet of GLA	339,000		274,000		1,125,000		750,000

Tenant improvements, leasing commissions and tenant concessions per square foot of GLA for new and renewal leases consist of the following for the three and nine months ended September 30, 2016 and 2015 (in per square foot of GLA):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
New leases:
Tenant improvements	$	20.28	$	20.59	$	21.10	$	22.94
Leasing commissions	4.91		4.47		4.29		3.82
Tenant concessions	3.81		5.61		3.92		5.39
Renewal leases:
Tenant improvements	$	9.46	$	11.27	$	6.19	$	7.30
Leasing commissions	2.32		1.44		1.57		1.09
Tenant concessions	1.71		2.54		1.06		1.70

The average term for new and renewal leases executed consist of the following for three and nine months ended September 30, 2016 and 2015 (in years):

	Three Months Ended September 30,		Nine Months Ended September 30,
	2016	2015	2016	2015
New leases	5.4	6.5	5.4	6.9
Renewal leases	4.5	5.0	4.8	5.7

Rental Expenses

For the three months ended September 30, 2016 and 2015, rental expenses attributable to our properties were $36.9 million and $32.9 million, respectively. For the nine months ended September 30, 2016 and 2015, rental expenses attributable to our properties were $105.3 million and $92.9 million, respectively. These increases in rental expenses were primarily due to $5.9 million and $18.0 million of additional rental expenses associated with our 2015 and 2016 acquisitions for the three and nine months ended September 30, 2016, respectively, partially offset by improved operating efficiencies and a decrease in rental expenses as a result of the buildings we sold during 2015 and 2016.

General and Administrative Expenses

For the three months ended September 30, 2016 and 2015, general and administrative expenses were $7.3 million and $6.4 million, respectively. For the nine months ended September 30, 2016 and 2015, general and administrative expenses were $20.9 million and $19.2 million, respectively. These increases in general and administrative expenses were primarily due to the increase in non-cash compensation expense. General and administrative expenses include such costs as salaries, corporate overhead and professional fees, among other items.

Acquisition-Related Expenses

For the three months ended September 30, 2016 and 2015, acquisition-related expenses were $1.1 million and $0.9 million, respectively. For the nine months ended September 30, 2016 and 2015, acquisition-related expenses were $5.0 million and $3.4 million, respectively. These increases in acquisition-related expenses were primarily due to increased acquisition activity during 2016.

29

Depreciation and Amortization Expense

For the three months ended September 30, 2016 and 2015, depreciation and amortization expense was $47.9 million and $40.5 million, respectively. For the nine months ended September 30, 2016 and 2015, depreciation and amortization expense was $130.4 million and $115.2 million, respectively. These increases in depreciation and amortization expense were primarily due to the increase in the size of our portfolio.

Interest Expense and Net Change in Fair Value of Derivative Financial Instruments

Interest expense excluding the impact of the net change in fair value of derivative financial instruments increased by $2.5 million during the three months ended September 30, 2016, compared to the three months ended September 30, 2015. This increase was primarily the result of higher average debt outstanding during the three months ended September 30, 2016, as a result of partially funding our investments over the last 12 months with debt and a change in the composition of debt, driven by an increase in long-term senior unsecured notes, including the $350.0 million 10-year senior unsecured notes issued in July 2016 at a coupon rate of 3.50%, offset by a reduction in the aggregate variable unsecured revolving credit facility borrowings and mortgage loans outstanding. During the three months ended September 30, 2016, the fair market value of our derivatives increased $1.3 million, compared to a net decrease of $2.4 million during the three months ended September 30, 2015.

Interest expense excluding the impact of the net change in fair value of derivative financial instruments increased by $2.6 million during the nine months ended September 30, 2016, compared to the nine months ended September 30, 2015. This increase was primarily the result of higher average debt outstanding during the nine months ended September 30, 2016, as a result of partially funding our investments over the last 12 months with debt and a change in the composition of debt, driven by an increase in long-term senior unsecured notes, including the $350.0 million 10-year senior unsecured notes issued in July 2016 at a coupon rate of 3.50%, offset by a reduction in the aggregate variable unsecured revolving credit facility borrowings and mortgage loans outstanding. During the nine months ended September 30, 2016, the fair market value of our derivatives decreased $2.1 million, compared to a net decrease of $3.1 million during the nine months ended September 30, 2015.

To achieve our objectives, we borrow at both fixed and variable rates. We also enter into derivative financial instruments, such as interest rate swaps, in order to mitigate our interest rate risk on a related financial instrument. We do not enter into derivative or interest rate transactions for speculative purposes. Derivatives not designated as hedges are not speculative and are used to manage our exposure to interest rate movements.

Gain on Sales of Real Estate

During the nine months ended September 30, 2016, we realized a gain of $4.2 million on the disposition of four senior care facilities. We did not have any dispositions during the three months ended September 30, 2016. During the three and nine months ended September 30, 2015, we realized a gain of $0.2 million from the disposition of six MOBs.

NOI and Same-Property Cash NOI

NOI increased$10.4 million to $81.5 million for the three months ended September 30, 2016, compared to the three months ended September 30, 2015. NOI increased$24.7 million to $233.6 million for the nine months ended September 30, 2016, compared to the nine months ended September 30, 2015. These increases were primarily due to $10.8 million and $25.6 millionof additional NOI from our 2015 and 2016 acquisitions for the three and nine months ended September 30, 2016, respectively, partially offset by a decrease in NOI as a result of the buildings we sold during 2015 and 2016 and a reduction in straight-line rent from properties we owned more than a year.

Same-Property Cash NOI increased$2.2 million to $68.6 million for the three months ended September 30, 2016, compared to the three months ended September 30, 2015. Same-Property Cash NOI increased$5.6 million to $192.8 million for the nine months ended September 30, 2016, compared to the nine months ended September 30, 2015. These increases were primarily the result of rent escalations, an increase in average occupancy and improved operating efficiencies.

Non-GAAP Financial Measures

FFO and Normalized FFO

We compute FFO in accordance with the current standards established by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as net income or loss attributable to common stockholders/unitholders (computed in accordance with GAAP), excluding gains or losses from sales of real estate property and impairment write-downs of depreciable assets, plus depreciation and amortization related to investments in real estate, and after adjustments for unconsolidated partnerships and joint ventures. We present this non-GAAP financial measure because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs. Historical cost accounting assumes that the value of real estate assets diminishes ratably over time. Since real estate values have historically risen or fallen based on market conditions, many industry investors have considered the presentation of operating results for real estate companies that use historical cost accounting to be insufficient by themselves. Because FFO excludes depreciation and amortization unique to real estate, among other items, it provides a perspective not immediately apparent from net income or loss attributable to common stockholders/

30

unitholders.

We also compute Normalized FFO, which excludes from FFO: (i) acquisition-related expenses; (ii) gain or loss on change in fair value of derivative financial instruments; (iii) gain or loss on extinguishment of debt; (iv) noncontrolling income or loss from partnership units included in diluted shares (only applicable to HTA); and (v) other normalizing items, which include items that are unusual and infrequent in nature. We present this non-GAAP financial measure because it allows for the comparison of our operating performance to other REITs and between periods on a consistent basis. Our methodology for calculating Normalized FFO may be different from the methods utilized by other REITs and, accordingly, may not be comparable to other REITs. Normalized FFO should not be considered as an alternative to net income or loss attributable to common stockholders/unitholders (computed in accordance with GAAP) as an indicator of our financial performance, nor is it indicative of cash available to fund cash needs. Normalized FFO should be reviewed in connection with other GAAP measurements.

The amounts included in the calculation of FFO and Normalized FFO are generally the same for HTALP and HTA, except for net income or loss attributable to common stockholders/unitholders, noncontrolling income or loss from partnership units included in diluted shares (only applicable to HTA) and the weighted average shares of HTA common stock or HTALP partnership units outstanding.

The following is the reconciliation of HTA’s FFO and Normalized FFO to net income attributable to common stockholders for the three and nine months ended September 30, 2016 and 2015 (in thousands, except per share data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Net income attributable to common stockholders	$	6,427		$	6,463		$	29,361		$	22,559
Depreciation and amortization expense related to investments in real estate	47,545			40,188			129,477			114,220
Gain on sale of real estate, net	—			(152		)	(4,212		)	(152		)
Impairment	—			—			—			1,655
FFO attributable to common stockholders	$	53,972		$	46,499		$	154,626		$	138,282
Acquisition-related expenses	1,122			907			4,997			3,365
(Gain) loss on change in fair value of derivative financial instruments, net	(1,306		)	2,383			2,144			3,079
Loss (gain) on extinguishment of debt, net	3,000			14			3,022			(107		)
Noncontrolling income from partnership units included in diluted shares	211			71			802			348
Other normalizing items, net (1)	133			127			117			216
Normalized FFO attributable to common stockholders	$	57,132		$	50,001		$	165,708		$	145,183
Net income attributable to common stockholders per diluted share	$	0.04		$	0.05		$	0.21		$	0.18
FFO adjustments per diluted share, net	0.34			0.31			0.91			0.90
FFO attributable to common stockholders per diluted share	$	0.38		$	0.36		$	1.12		$	1.08
Normalized FFO adjustments per diluted share, net	0.02			0.03			0.08			0.06
Normalized FFO attributable to common stockholders per diluted share	$	0.40		$	0.39		$	1.20		$	1.14
Weighted average diluted common shares outstanding	143,138			128,793			138,314			127,680
(1) For the three and nine months ended September 30, 2016 and all periods thereafter, other normalizing items excludes lease termination fees as they are deemed to be generated in the ordinary course of business.

31

The following is the reconciliation of HTALP’s FFO and Normalized FFO to net income attributable to common unitholders for the three and nine months ended September 30, 2016 and 2015 (in thousands, except per unit data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Net income attributable to common unitholders	$	6,638		$	6,534		$	30,163		$	22,907
Depreciation and amortization expense related to investments in real estate	47,545			40,188			129,477			114,220
Gain on sale of real estate, net	—			(152		)	(4,212		)	(152		)
Impairment	—			—			—			1,655
FFO attributable to common unitholders	$	54,183		$	46,570		$	155,428		$	138,630
Acquisition-related expenses	1,122			907			4,997			3,365
(Gain) loss on change in fair value of derivative financial instruments, net	(1,306		)	2,383			2,144			3,079
Loss (gain) on extinguishment of debt, net	3,000			14			3,022			(107		)
Other normalizing items, net (1)	133			127			117			216
Normalized FFO attributable to common unitholders	$	57,132		$	50,001		$	165,708		$	145,183
Net income attributable to common unitholders per diluted unit	$	0.05		$	0.05		$	0.22		$	0.18
FFO adjustments per diluted unit, net	0.33			0.31			0.90			0.90
FFO attributable to common unitholders per diluted unit	$	0.38		$	0.36		$	1.12		$	1.08
Normalized FFO adjustments per diluted unit, net	0.02			0.03			0.08			0.06
Normalized FFO attributable to common unitholders per diluted unit	$	0.40		$	0.39		$	1.20		$	1.14
Weighted average diluted common units outstanding	143,137			128,793			138,314			127,781
(1) For the three and nine months ended September 30, 2016 and all periods thereafter, other normalizing items excludes lease termination fees as they are deemed to be generated in the ordinary course of business.

NOI, Cash NOI and Same-Property Cash NOI

NOI is a non-GAAP financial measure that is defined as net income or loss (computed in accordance with GAAP) before: (i) general and administrative expenses; (ii) acquisition-related expenses; (iii) depreciation and amortization expense; (iv) impairment; (v) interest expense and net change in fair value of derivative financial instruments; (vi) gain or loss on sales of real estate; (vii) gain or loss on extinguishment of debt; and (viii) other income or expense. We believe that NOI provides an accurate measure of the operating performance of our operating assets because NOI excludes certain items that are not associated with the management of our properties. Additionally, we believe that NOI is a widely accepted measure of comparative operating performance of REITs. However, our use of the term NOI may not be comparable to that of other REITs as they may have different methodologies for computing this amount. NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. NOI should be reviewed in connection with other GAAP measurements.

Cash NOI is a non-GAAP financial measure which excludes from NOI: (i) straight-line rent adjustments and (ii) amortization of below and above market leases/leasehold interests and lease termination fees. Contractual base rent, contractual rent increases, contractual rent concessions and changes in occupancy or lease rates upon commencement and expiration of leases are a primary driver of our revenue performance. We believe that Cash NOI, which removes the impact of straight-line rent adjustments, provides another measurement of the operating performance of our operating assets. Additionally, we believe that Cash NOI is a widely accepted measure of comparative operating performance of REITs. However, our use of the term Cash NOI may not be comparable to that of other REITs as they may have different methodologies for computing this amount. Cash NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. Cash NOI should be reviewed in connection with other GAAP measurements.

To facilitate the comparison of Cash NOI between periods, we calculate comparable amounts for a subset of our owned properties referred to as “Same-Property”. Same-Property Cash NOI excludes properties which have not been owned and operated by us during the entire span of all periods presented, excluding properties intended for disposition in the near term, notes receivable interest income and certain non-routine items. Same-Property Cash NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. Same-Property Cash NOI should be reviewed in connection with other GAAP measurements.

32

The following is the reconciliation of HTA’s and HTALP’s NOI, Cash NOI and Same-Property Cash NOI to net income for the three and nine months ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Net income	$	6,639		$	6,554		$	30,191		$	22,984
General and administrative expenses	7,293			6,430			20,879			19,229
Acquisition-related expenses	1,122			907			4,997			3,365
Depreciation and amortization expense	47,864			40,518			130,430			115,179
Impairment	—			—			—			1,655
Interest expense and net change in fair value of derivative financial instruments	15,632			16,822			48,503			46,856
Gain on sale of real estate, net	—			(152		)	(4,212		)	(152		)
Loss (gain) on extinguishment of debt, net	3,000			14			3,022			(107		)
Other income	(95		)	(72		)	(220		)	(91		)
NOI	$	81,455		$	71,021		$	233,590		$	208,918
Straight-line rent adjustments, net	(1,161		)	(1,750		)	(3,636		)	(5,835		)
Amortization of below and above market leases/leasehold interests, net and lease termination fees (1)	3			598			497			1,739
Cash NOI	$	80,297		$	69,869		$	230,451		$	204,822
Notes receivable interest income	(68		)	—			(68		)	—
Non Same-Property Cash NOI	(11,590		)	(3,398		)	(37,569		)	(17,615		)
Same-Property Cash NOI (2)	$	68,639		$	66,471		$	192,814		$	187,207
(1) For the three and nine months ended September 30, 2016 and all periods thereafter, Cash NOI includes lease termination fees as they are deemed to be generated in the ordinary course of business.
(2) Same-Property includes 283 and 275 buildings for the three and nine months ended September 30, 2016 and 2015.

Liquidity and Capital Resources

Our primary sources of cash include: (i) cash flow from operations; (ii) borrowings under our unsecured revolving credit facility; (iii) net proceeds from the issuances of debt and equity securities; and (iv) proceeds from our dispositions. During the next 12 months our primary uses of cash are expected to include: (i) the funding of acquisitions of MOBs and other facilities that serve the healthcare industry; (ii) capital expenditures; (iii) the payment of operating expenses; (iv) debt service payments, including principal payments; and (v) the payment of dividends to our stockholders. We anticipate cash flow from operations, restricted cash and reserve accounts and our unsecured revolving credit facility, if needed, will be sufficient to fund our operating expenses, capital expenditures and dividends to stockholders. Investments and maturing indebtedness may require funds from the issuance of debt and/or equity securities or proceeds from sales of real estate.

As of September 30, 2016, we had liquidity of $835.4 million, including $817.5 million available under our unsecured revolving credit facility (includes the impact of $5.5 million of outstanding letters of credit) and $17.9 million of cash and cash equivalents.

As of September 30, 2016, $177.1 million was available for issuance under our $300.0 million ATM program. In addition, we had unencumbered properties with a gross book value of $3.6 billion. The unencumbered properties may be used as collateral to secure additional financings in future periods or to refinance our current debt as it becomes due. Our ability to raise funds from future debt and equity issuances is dependent on our investment grade credit ratings, general economic and market conditions and our operating performance.

When we acquire a property, we prepare a capital plan that contemplates the estimated capital needs of that investment. In addition to operating expenses, capital needs may also include costs of refurbishment, tenant improvements or other major capital expenditures. The capital plan for each investment will be adjusted through ongoing, regular reviews of our portfolio or as necessary to respond to unanticipated additional capital needs. As of September 30, 2016, we estimate that our expenditures for capital improvements for the remainder of 2016 will range from $5.0 million to $10.0 million depending on leasing activity. As of September 30, 2016, we had $7.4 million of restricted cash and reserve accounts for such capital expenditures. We cannot provide assurance, however, that we will not exceed these estimated expenditure levels.

33

If we experience lower occupancy levels, reduced rental rates, reduced revenues as a result of asset sales, or increased capital expenditures and leasing costs compared to historical levels due to competitive market conditions for new and renewal leases, the effect would be a reduction of net cash provided by operating activities. If such a reduction of net cash provided by operating activities is realized, we may have a cash flow deficit in subsequent periods. Our estimate of net cash available is based on various assumptions which are difficult to predict, including the levels of our leasing activity and related leasing costs. Any changes in these assumptions could impact our financial results and our ability to fund working capital and unanticipated cash needs.

Cash Flows

The following is a summary of our cash flows for the nine months ended September 30, 2016 and 2015 (in thousands):

	Nine Months Ended September 30,
	2016			2015			Change
Cash and cash equivalents - beginning of period	$	13,070		$	10,413		$	2,657
Net cash provided by operating activities	148,257			138,659			9,598
Net cash used in investing activities	(541,080		)	(234,164		)	(306,916		)
Net cash provided by financing activities	397,691			96,238			301,453
Cash and cash equivalents - end of period	$	17,938		$	11,146		$	6,792

Net cash provided by operating activities increased in 2016 primarily due to the impact of our 2015 and 2016 acquisitions, contractual rent increasesand improved operating efficiencies, partially offset by our 2015 and 2016 dispositions. We anticipate cash flows from operating activities to increaseas a result of the above items and continued leasing activity in our existing portfolio.

For the nine months ended September 30, 2016, net cash used in investing activities primarily related to the investment in real estate of $532.5 million and capital expenditures of $34.1 million, partially offset by proceeds from the sale of real estate of $23.4 million. For the nine months ended September 30, 2015, net cash used in investing activities primarily related to the investment in real estate of $253.1 million and capital expenditures of $17.3 million, partially offset by the proceeds from the sale of real estate of $33.3 million. We anticipate cash flows used in investing activities to increase as we continue to acquire more properties.

For the nine months ended September 30, 2016, net cash provided by financing activities primarily related to the net proceeds of shares of common stock issued of $418.9 million and proceeds from unsecured senior notes of $347.7 million, partially offset by net payments on our unsecured revolving credit facility of $191.0 million, dividends paid to holders of our common stock of $116.7 million and payments on our secured mortgage loans of $98.5 million. For the nine months ended September 30, 2015, net cash provided by financing activities primarily related to net borrowings of $240.0 million on our Unsecured Credit Agreement and the net proceeds of shares of common stock issued of $44.3 million, partially offset by dividends paid to holders of our common stock of $108.9 million and payments on our mortgage and term loans of $76.1 million.

Dividends

The amount of dividends HTA pays to its stockholders is determined by its Board of Directors, in its sole discretion, and is dependent on a number of factors, including funds available, our financial condition, capital expenditure requirements and annual dividend distribution requirements needed to maintain our status as a REIT under the Internal Revenue Code of 1986, as amended. HTA has paid monthly or quarterly dividends since February 2007, and if our investments produce sufficient cash flow, we expect to continue to pay dividends to our stockholders. Because our cash available for dividend distributions in any year may be less than 90% of our taxable income for the year, we may obtain the necessary funds through borrowings, issuing new securities or selling assets to pay out enough of our taxable income to satisfy our dividend distribution requirement. HTA’s organizational documents do not establish a limit on dividends that may constitute a return of capital for federal income tax purposes. The dividend HTA pays to its stockholders is equal to the distributions received from HTALP in accordance with the terms of HTALP’s partnership agreement. It is HTA’s intention to continue to pay dividends. However, HTA’s Board of Directors may reduce our dividend rate and HTA cannot guarantee the timing and amount of dividends that it may pay in the future, if any.

For the nine months ended September 30, 2016, HTA paid cash dividends of $116.7 million. In October 2016, HTA paid cash dividends of $42.5 million for the quarter ended September 30, 2016. On October 25, 2016, HTA declared a quarterly cash dividend of $0.30 per share to be paid on January 10, 2017 to stockholders of record of its common stock on January 3, 2017.

34

Financing

We have historically maintained a low leveraged balance sheet and intend to continue to maintain this structure over the long run. However, our total leverage may fluctuate on a short term basis as we execute our business strategy. As of September 30, 2016, our leverage ratio of debt to capitalization was 26.4%.

As of September 30, 2016, we had debt outstanding of $1.7 billion and the weighted average interest rate was 3.35% per annum, inclusive of the impact of our interest rate swaps. The following is a summary of our unsecured and secured debt. See Note 7 - Debt to our accompanying condensed consolidated financial statements for a further discussion of our debt.

Unsecured Revolving Credit Facility

As of September 30, 2016, $817.5 million was available on our unsecured revolving credit facility. Our unsecured revolving credit facility matures in January 2020. In February 2015, we executed an amendment to the Unsecured Credit Agreement which added an additional lender and increased the amount available under the unsecured revolving credit facility by $50.0 million to $850.0 million. The other existing terms of the Unsecured Credit Agreement were unchanged.

Unsecured Term Loans

As of September 30, 2016, we had $500.0 million of unsecured term loans outstanding, comprised of a $300.0 million term loan under our Unsecured Credit Agreement maturing in 2019 and a $200.0 million unsecured term loan maturing in 2023. The $300.0 million term loan includes a one-year extension exercisable at the option of the borrower, subject to certain conditions.

Unsecured Senior Notes

As of September 30, 2016, we had $950.0 million of unsecured senior notes outstanding, comprised of $300.0 million of unsecured senior notes maturing in 2021, $300.0 million of unsecured senior notes maturing in 2023, and $350.0 million of unsecured senior notes maturing in 2026.

Mortgage Loans

During the nine months ended September 30, 2016, we made payments of $98.5 million on our mortgage loans and have $1.4 million of principal payments due on current outstanding indebtedness during the remainder of 2016.

Commitments and Contingencies

There have been no material changes from the commitments and contingencies disclosed in our 2015 Annual Report on Form 10-K.

Debt Service Requirements

We are required by the terms of our applicable loan agreements to meet certain financial covenants, such as minimum net worth and liquidity, and reporting requirements, among others. As of September 30, 2016, we believe that we were in compliance with all such covenants and we are not aware of any covenants that we are reasonably likely not to satisfy.

Off-Balance Sheet Arrangements

As of and during the nine months ended September 30, 2016, we had no off-balance sheet arrangements.

Inflation

We are exposed to inflation risk as income from future long-term leases is the primary source of our cash flows from operations. There are provisions in the majority of our tenant leases that protect us from the impact of normal inflation. These provisions include rent escalations, reimbursement billings for operating expense pass-through charges and real estate tax and insurance reimbursements on a per square foot allowance. However, due to the long-term nature of our leases, among other factors, the leases may not reset frequently enough to cover inflation.

35

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There were no material changes in the information regarding market risk that was provided in our 2015 Annual Report on Form 10-K. The table below presents, as of September 30, 2016, the principal amounts of our fixed and variable debt and the weighted average interest rates, excluding the impact of interest rate swaps, by year of expected maturity to evaluate the expected cash flows and sensitivity to interest rate changes (in thousands, except interest rates):

	Expected Maturity Date
	2016			2017			2018			2019			2020			Thereafter			Total
Fixed rate debt	$	1,197		$	86,281		$	3,283		$	3,461		$	22,673		$	1,042,902		$	1,159,797
Weighted average interest rate on fixed rate debt (per annum)	5.52		%	5.87		%	5.31		%	5.32		%	6.10		%	3.67		%	3.89		%
Variable rate debt	$	236		$	987		$	1,050		$	301,119		$	54,123		$	208,625		$	566,140
Weighted average interest rate on variable rate debt based on forward rates in effect as of September 30, 2016 (per annum)	2.48		%	2.64		%	2.72		%	2.25		%	1.11		%	2.77		%	1.86		%

As of September 30, 2016, we had $1.7 billion fixed and variable rate debt with interest rates ranging from 1.55% to 6.26% per annum and a weighted average interest rate of 3.22% per annum, excluding the impact of interest rate swaps. We had $1,159.8 million (excluding net premium/discount and deferred financing costs) of fixed rate debt with a weighted average interest rate of 3.89% per annum and $566.1 million (excluding net premium/discount and deferred financing costs) of variable rate debt with a weighted average interest rate of 1.86% per annum as of September 30, 2016, excluding the impact of interest rate swaps.

As of September 30, 2016, the fair value of our fixed rate debt was $1,204.7 million and the fair value of our variable rate debt was $576.9 million based upon prevailing market rates as of September 30, 2016.

As of September 30, 2016, we had interest rate swaps outstanding that effectively fix $191.0 million of our variable rate debt. Including the impact of these interest rate swaps, the effective rate on our variable rate and total debt is 2.25% and 3.35% per annum, respectively.

In addition to changes in interest rates, the value of our future properties is subject to fluctuations based on changes in local and regional economic conditions and changes in the creditworthiness of tenants, which may affect our ability to refinance our debt if necessary.

Item 4. Controls and Procedures

Healthcare Trust of America, Inc.

HTA’s management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to HTA’s management, including HTA’s Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer and principal accounting officer), to allow timely decisions regarding required disclosure.

As of September 30, 2016, an evaluation was conducted by HTA under the supervision and with the participation of its management, including HTA’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, HTA’s Chief Executive Officer and the Chief Financial Officer concluded that HTA’s disclosure controls and procedures were effective.

There were no changes in HTA’s internal control over financial reporting that occurred during the quarter ended September 30, 2016 that have materially affected, or are reasonably believed to be likely to materially affect, HTA’s internal control over financial reporting.

October 26, 2016

36

Healthcare Trust of America Holdings, LP

HTALP’s management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to HTALP’s management, including HTA’s Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer and principal accounting officer), to allow timely decisions regarding required disclosure.

As of September 30, 2016, an evaluation was conducted by HTALP under the supervision and with the participation of its management, including HTA’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, HTA’s Chief Executive Officer and the Chief Financial Officer, on behalf of HTA in its capacity as general partner of HTALP, concluded that HTALP’s disclosure controls and procedures were effective.

There were no changes in HTALP’s internal control over financial reporting that occurred during the quarter ended September 30, 2016 that have materially affected, or are reasonably believed to be likely to materially affect, HTALP’s internal control over financial reporting.

October 26, 2016

37

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are subject to claims and litigation arising in the ordinary course of business. We do not believe any liability from any reasonably foreseeable disposition of such claims and litigation, individually or in the aggregate, would have a material adverse effect on our accompanying condensed consolidated financial statements.

Item 1A. Risk Factors

There have been no material changes from the risk factors previously disclosed in our 2015 Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

During the three months ended September 30, 2016, HTA repurchased shares of its common stock as follows:

Period	Total Number of Shares Purchased (1) (2)	Average Price Paid per Share (1) (2)		Total Number of Shares Purchased as Part of Publicly Announced Plan or Program	Maximum Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs
July 1, 2016 to July 31, 2016	940	$	32.51	—	—
August 1, 2016 to August 31, 2016	1,534	34.05		—	—
September 1, 2016 to September 30, 2016	1,699	32.50		—	—
(1) Purchases mainly represent shares withheld to satisfy withholding obligations on the vesting of restricted shares. The price paid per share was the then closing price of our common stock on the NYSE.
(2) For each share of common stock redeemed by HTA, HTALP redeems a corresponding number of units in the operating partnership. Therefore, the units in the operating partnership repurchased by HTALP are the same as the shares of common stock repurchased by HTA as shown above.

Item 6. Exhibits

The exhibits listed on the Exhibit Index (following the signatures section of this Quarterly Report) are included, and incorporated by reference, in this Quarterly Report.

38

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned thereunto duly authorized.

	Healthcare Trust of America, Inc.
By:	/s/ Scott D. Peters	Chief Executive Officer, President and Chairman
	Scott D. Peters	(Principal Executive Officer)
Date:	October 26, 2016
By:	/s/ Robert A. Milligan	Chief Financial Officer
	Robert A. Milligan	(Principal Financial Officer and Principal Accounting Officer)
Date:	October 26, 2016

	Healthcare Trust of America Holdings, LP
By:	Healthcare Trust of America, Inc.,
	its General Partner
By:	/s/ Scott D. Peters	Chief Executive Officer, President and Chairman
	Scott D. Peters	(Principal Executive Officer)
Date:	October 26, 2016
By:	/s/ Robert A. Milligan	Chief Financial Officer
	Robert A. Milligan	(Principal Financial Officer and Principal Accounting Officer)
Date:	October 26, 2016

39

EXHIBIT INDEX

The following exhibits are included, or incorporated by reference, in this Quarterly Report for the quarter ended September 30, 2016 (and are numbered in accordance with Item 601 of Regulation S-K).

1.1	Underwriting Agreement, dated as of September 7, 2016, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and Wells Fargo Securities, LLC, Jefferies LLC and BMO Capital Markets Corp., as representatives of the several underwriters named therein, on the other hand (included as Exhibit 1.1 to our Current Report on Form 8-K filed on September 13, 2016 and incorporated herein by reference).
5.1	Opinion of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on September 13, 2016 and incorporated herein by reference).
10.1	Third Modification to Credit Agreement (included as Exhibit 10.1 in our Form 8-K filed on September 29, 2016 and incorporated herein by reference).
23.1	Consent of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on September 13, 2016 and incorporated herein by reference).
31.1*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
31.2*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
31.3*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
31.4*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
32.1**	Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Inc.
32.2**	Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
32.3**	Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
32.4**	Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
101.INS*	XBRL Instance Document.
101.SCH*	XBRL Taxonomy Extension Schema Document.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.
*	Filed herewith.
**	Furnished herewith.

40

EX-31.1

Exhibit 31.1

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Scott D. Peters, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman

Date: October 26, 2016

EX-31.2

Exhibit 31.2

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Robert A. Milligan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer

Date: October 26, 2016

EX-31.3

Exhibit 31.3

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Scott D. Peters, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: October 26, 2016

EX-31.4

Exhibit 31.4

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Robert A. Milligan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: October 26, 2016

EX-32.1

Exhibit 32.1

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc., or the Company, for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Scott D. Peters, Chief Executive Officer, President and Chairman of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman

Date: October 26, 2016

A signed original of this written statement required by Section 906 has been provided to Healthcare Trust of America, Inc. and will be retained by Healthcare Trust of America, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc., or the Company, for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Robert A. Milligan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer

Date: October 26, 2016

A signed original of this written statement required by Section 906 has been provided to Healthcare Trust of America, Inc. and will be retained by Healthcare Trust of America, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.3

Exhibit 32.3

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP, or the Company, for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Scott D. Peters, Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: October 26, 2016

A signed original of this written statement required by Section 906 has been provided to Healthcare Trust of America, Inc. and will be retained by Healthcare Trust of America, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.4

Exhibit 32.4

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP, or the Company, for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Robert A. Milligan, Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: October 26, 2016

A signed original of this written statement required by Section 906 has been provided to Healthcare Trust of America, Inc. and will be retained by Healthcare Trust of America, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 24, 2016
Entity Information [Line Items]
Entity Registrant Name	HEALTHCARE TRUST OF AMERICA, INC.
Entity Central Index Key	0001360604
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		141,727,903
Healthcare Trust of America Holdings, LP (HTALP)
Entity Information [Line Items]
Entity Registrant Name	Healthcare Trust of America Holdings, LP
Entity Central Index Key	0001495491
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Real estate investments:
Land	$ 381,745	$ 303,706
Building and improvements	3,406,897	2,901,157
Lease intangibles	466,434	430,749
Real estate investments, gross	4,255,076	3,635,612
Accumulated depreciation and amortization	(779,378)	(676,144)
Real estate investments, net	3,475,698	2,959,468
Cash and cash equivalents	17,938	13,070
Restricted cash and escrow deposits	13,689	15,892
Receivables and other assets, net	160,837	141,703
Other intangibles, net	47,728	42,167
Total assets	3,715,890	3,172,300
Liabilities:
Debt	1,712,598	1,590,696
Accounts payable and accrued liabilities	104,202	94,933
Derivative financial instruments - interest rate swaps	4,866	2,370
Security deposits, prepaid rent and other liabilities	44,828	46,295
Intangible liabilities, net	36,928	26,611
Total liabilities	1,903,422	1,760,905
Commitments and contingencies
Redeemable noncontrolling interests	9,215	4,437
Equity/Partners' Capital:
Preferred stock, $0.01 par value; 200,000,000 shares authorized; none issued and outstanding	0	0
Class A common stock, $0.01 par value; 1,000,000,000 shares authorized; 141,728,448 and 127,026,839 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	1,417	1,270
Additional paid-in capital	2,753,566	2,328,806
Cumulative dividends in excess of earnings	(1,042,977)	(950,652)
Total stockholders’ equity	1,712,006	1,379,424
Noncontrolling interests	91,247	27,534
Total equity	1,803,253	1,406,958
Total liabilities and equity/partners' capital	3,715,890	3,172,300
Healthcare Trust of America Holdings, LP (HTALP)
Real estate investments:
Land	381,745	303,706
Building and improvements	3,406,897	2,901,157
Lease intangibles	466,434	430,749
Real estate investments, gross	4,255,076	3,635,612
Accumulated depreciation and amortization	(779,378)	(676,144)
Real estate investments, net	3,475,698	2,959,468
Cash and cash equivalents	17,938	13,070
Restricted cash and escrow deposits	13,689	15,892
Receivables and other assets, net	160,837	141,703
Other intangibles, net	47,728	42,167
Total assets	3,715,890	3,172,300
Liabilities:
Debt	1,712,598	1,590,696
Accounts payable and accrued liabilities	104,202	94,933
Derivative financial instruments - interest rate swaps	4,866	2,370
Security deposits, prepaid rent and other liabilities	44,828	46,295
Intangible liabilities, net	36,928	26,611
Total liabilities	1,903,422	1,760,905
Commitments and contingencies
Redeemable noncontrolling interests	9,215	4,437
Equity/Partners' Capital:
Limited partners’ capital, 4,323,095 and 1,929,942 units issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	90,977	27,264
General partners’ capital, 141,728,448 and 127,026,839 units issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	1,712,276	1,379,694
Total partners’ capital	1,803,253	1,406,958
Total liabilities and equity/partners' capital	$ 3,715,890	$ 3,172,300

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Equity:
Preferred stock, par value (usd per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	200,000,000	200,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Healthcare Trust of America Holdings, LP (HTALP)
Partners’ Capital:
Limited partner's capital, units issued	4,323,095	1,929,942
Limited partner's capital, units outstanding	4,323,095	1,929,942
General partner's capital, units issued	141,728,448	127,026,839
General partner's capital, units outstanding	141,728,448	127,026,839
Class A Common Stock
Equity:
Common stock, par value (usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	141,728,448	127,026,839
Common stock, shares outstanding	141,728,448	127,026,839

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Rental income		$ 118,252	$ 103,875	$ 338,646	$ 301,570
Interest and other operating income		88	67	243	203
Total revenues		118,340	103,942	338,889	301,773
Expenses:
Rental		36,885	32,921	105,299	92,855
General and administrative		7,293	6,430	20,879	19,229
Acquisition-related		1,122	907	4,997	3,365
Depreciation and amortization		47,864	40,518	130,430	115,179
Impairment		0	0	0	1,655
Total expenses		93,164	80,776	261,605	232,283
Income before other income (expense)		25,176	23,166	77,284	69,490
Interest expense:
Interest related to derivative financial instruments		(552)	(903)	(1,856)	(2,278)
Gain (loss) on change in fair value of derivative financial instruments, net		1,306	(2,383)	(2,144)	(3,079)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments		754	(3,286)	(4,000)	(5,357)
Interest related to debt		(16,386)	(13,536)	(44,503)	(41,499)
Gain on sale of real estate, net		0	152	4,212	152
(Loss) gain on extinguishment of debt, net		(3,000)	(14)	(3,022)	107
Other income		95	72	220	91
Net income		6,639	6,554	30,191	22,984
Net income attributable to noncontrolling interests	[1]	(212)	(91)	(830)	(425)
Net income attributable to common stockholders/unitholders		$ 6,427	$ 6,463	$ 29,361	$ 22,559
Earnings per common share/unit - basic:
Net income attributable to common stockholders/unitholders (in usd per share)		$ 0.05	$ 0.05	$ 0.22	$ 0.18
Earnings per common share/unit - diluted:
Net income attributable to common stockholders/unitholders (in usd per share)		$ 0.04	$ 0.05	$ 0.21	$ 0.18
Weighted average common shares/units outstanding:
Basic (in shares/units)		138,807	126,863	134,905	125,750
Diluted (in shares/units)		143,138	128,793	138,314	127,680
Dividends declared per common share (in usd per share)		$ 0.300	$ 0.295	$ 0.890	$ 0.875
Healthcare Trust of America Holdings, LP (HTALP)
Revenues:
Rental income		$ 118,252	$ 103,875	$ 338,646	$ 301,570
Interest and other operating income		88	67	243	203
Total revenues		118,340	103,942	338,889	301,773
Expenses:
Rental		36,885	32,921	105,299	92,855
General and administrative		7,293	6,430	20,879	19,229
Acquisition-related		1,122	907	4,997	3,365
Depreciation and amortization		47,864	40,518	130,430	115,179
Impairment		0	0	0	1,655
Total expenses		93,164	80,776	261,605	232,283
Income before other income (expense)		25,176	23,166	77,284	69,490
Interest expense:
Interest related to derivative financial instruments		(552)	(903)	(1,856)	(2,278)
Gain (loss) on change in fair value of derivative financial instruments, net		1,306	(2,383)	(2,144)	(3,079)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments		754	(3,286)	(4,000)	(5,357)
Interest related to debt		(16,386)	(13,536)	(44,503)	(41,499)
Gain on sale of real estate, net		0	152	4,212	152
(Loss) gain on extinguishment of debt, net		(3,000)	(14)	(3,022)	107
Other income		95	72	220	91
Net income		6,639	6,554	30,191	22,984
Net income attributable to noncontrolling interests		(1)	(20)	(28)	(77)
Net income attributable to common stockholders/unitholders		$ 6,638	$ 6,534	$ 30,163	$ 22,907
Earnings per common share/unit - basic:
Net income attributable to common stockholders/unitholders (in usd per share)		$ 0.05	$ 0.05	$ 0.22	$ 0.18
Earnings per common share/unit - diluted:
Net income attributable to common stockholders/unitholders (in usd per share)		$ 0.05	$ 0.05	$ 0.22	$ 0.18
Weighted average common shares/units outstanding:
Basic (in shares/units)		143,137	128,793	138,314	127,781
Diluted (in shares/units)		143,137	128,793	138,314	127,781
Dividends declared per common share (in usd per share)		$ 0.300	$ 0.295	$ 0.890	$ 0.875

[1] Includes amounts attributable to redeemable noncontrolling interests.

XML

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Class A Common Stock	Common Stock Class A Common Stock	Additional Paid-In Capital	Cumulative Dividends in Excess of Earnings	Total Stockholders’ Equity	Noncontrolling Interests
Beginning balance at Dec. 31, 2014	$ 1,476,421		$ 1,251	$ 2,281,932	$ (836,044)	$ 1,447,139	$ 29,282
Beginning balance (in shares) at Dec. 31, 2014			125,087,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net	43,649		$ 18	43,631		43,649
Issuance of common stock, net (in shares)			1,800,000
Share-based award transactions, net	4,462		$ 2	4,460		4,462
Share-based award transactions, net (in shares)			200,000
Repurchase and cancellation of common stock	(1,322)		$ (1)	(1,321)		(1,322)
Repurchase and cancellation of common stock (in shares)			(49,000)
Dividends declared	(111,766)				(110,071)	(110,071)	(1,695)
Net income	22,907				22,559	22,559	348
Ending balance at Sep. 30, 2015	1,434,351		$ 1,270	2,328,702	(923,556)	1,406,416	27,935
Ending balance (in shares) at Sep. 30, 2015			127,038,000
Beginning balance at Dec. 31, 2015	1,406,958		$ 1,270	2,328,806	(950,652)	1,379,424	27,534
Beginning balance (in shares) at Dec. 31, 2015		127,026,839	127,027,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net	417,163		$ 141	417,022		417,163
Issuance of common stock, net (in shares)			14,138,000
Issuance of operating partnership units in connection with an acquisition	71,754						71,754
Share-based award transactions, net	5,136		$ 4	5,132		5,136
Share-based award transactions, net (in shares)			393,000
Repurchase and cancellation of common stock	(2,425)		$ (1)	(2,424)		(2,425)
Repurchase and cancellation of common stock (in shares)			(87,000)
Redemption of noncontrolling interest and other	(676)		$ 3	5,030		5,033	(5,709)
Redemption of noncontrolling interest and other (in shares)			257,000
Dividends declared	(124,820)				(121,686)	(121,686)	(3,134)
Net income	30,163				29,361	29,361	802
Ending balance at Sep. 30, 2016	$ 1,803,253		$ 1,417	$ 2,753,566	$ (1,042,977)	$ 1,712,006	$ 91,247
Ending balance (in shares) at Sep. 30, 2016		141,728,448	141,728,000

XML

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS' CAPITAL - USD ($) $ in Thousands	Total	Healthcare Trust of America Holdings, LP (HTALP)	Healthcare Trust of America Holdings, LP (HTALP) General Partners’ Capital	Healthcare Trust of America Holdings, LP (HTALP) Limited Partners’ Capital
Balance as of beginning of period at Dec. 31, 2014		$ 1,476,421	$ 1,447,409	$ 29,012
Balance as of beginning of period (in units) at Dec. 31, 2014			125,087,000	2,155,000
Increase (Decrease) in Partners' Capital [Roll Forward]
Issuance of general partner units, net		43,649	$ 43,649
Issuance of general partner units, net (in units)			1,800,000
Share-based award transactions, net		4,462	$ 4,462
Share-based award transactions, net (in units)			200,000	(225,000)
Redemption and cancellation of general partner units		(1,322)	$ (1,322)
Redemption and cancellation of general partner units (in units)			(49,000)
Distributions declared		(111,766)	$ (110,071)	$ (1,695)
Net income	$ 22,559	22,907	22,559	348
Balance as of end of period at Sep. 30, 2015		1,434,351	$ 1,406,686	$ 27,665
Balance as of end of period (in units) at Sep. 30, 2015			127,038,000	1,930,000
Balance as of beginning of period at Dec. 31, 2015		1,406,958	$ 1,379,694	$ 27,264
Balance as of beginning of period (in units) at Dec. 31, 2015			127,027,000	1,930,000
Increase (Decrease) in Partners' Capital [Roll Forward]
Issuance of general partner units, net		417,163	$ 417,163
Issuance of general partner units, net (in units)			14,138,000
Issuance of limited partner units in connection with an acquisition		$ 71,754		$ 71,754
Issuance of limited partner units in connection with an acquisition (in units)		2,650,409		2,650,000
Share-based award transactions, net		$ 5,136	$ 5,136
Share-based award transactions, net (in units)			393,000
Redemption and cancellation of general partner units		(2,425)	$ (2,425)
Redemption and cancellation of general partner units (in units)			(87,000)
Redemption of limited partner units and other		(676)	$ 5,033	$ (5,709)
Redemption of limited partner units and other (in units)			257,000	(257,000)
Distributions declared		(124,820)	$ (121,686)	$ (3,134)
Net income	$ 29,361	30,163	29,361	802
Balance as of end of period at Sep. 30, 2016		$ 1,803,253	$ 1,712,276	$ 90,977
Balance as of end of period (in units) at Sep. 30, 2016			141,728,000	4,323,000

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income	$ 30,191	$ 22,984
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	128,728	112,711
Share-based compensation expense	5,136	4,462
Bad debt expense	508	743
Gain on sale of real estate, net	(4,212)	(152)
Impairment	0	1,655
Loss (gain) on extinguishment of debt, net	3,022	(107)
Change in fair value of derivative financial instruments	2,144	3,079
Changes in operating assets and liabilities:
Receivables and other assets, net	(14,051)	(6,021)
Accounts payable and accrued liabilities	3,598	(4,124)
Prepaid rent and other liabilities	(6,807)	3,429
Net cash provided by operating activities	148,257	138,659
Cash flows from investing activities:
Investments in real estate	(532,527)	(253,107)
Proceeds from the sale of real estate	23,368	33,279
Capital expenditures	(34,064)	(17,330)
Restricted cash, escrow deposits and other assets	2,143	2,994
Net cash used in investing activities	(541,080)	(234,164)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	513,000	387,000
Payments on unsecured revolving credit facility	(704,000)	(247,000)
Proceeds from unsecured senior notes	347,725	0
Borrowings on unsecured term loans	200,000	100,000
Payments on unsecured term loans	(155,000)	0
Payments on secured mortgage loans	(98,453)	(76,149)
Deferred financing costs	(3,039)	(289)
Security deposits	862	145
Proceeds from issuance of common stock	418,891	44,324
Repurchase and cancellation of common stock	(2,425)	(1,322)
Dividends paid	(116,655)	(108,891)
Distributions paid to noncontrolling interest of limited partners	(2,724)	(1,580)
Redemption of redeemable noncontrolling interest	(491)	0
Net cash provided by financing activities	397,691	96,238
Net change in cash and cash equivalents	4,868	733
Cash and cash equivalents - beginning of period	13,070	10,413
Cash and cash equivalents - end of period	17,938	11,146
Healthcare Trust of America Holdings, LP (HTALP)
Cash flows from operating activities:
Net income	30,191	22,984
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	128,728	112,711
Share-based compensation expense	5,136	4,462
Bad debt expense	508	743
Gain on sale of real estate, net	(4,212)	(152)
Impairment	0	1,655
Loss (gain) on extinguishment of debt, net	3,022	(107)
Change in fair value of derivative financial instruments	2,144	3,079
Changes in operating assets and liabilities:
Receivables and other assets, net	(14,051)	(6,021)
Accounts payable and accrued liabilities	3,598	(4,124)
Prepaid rent and other liabilities	(6,807)	3,429
Net cash provided by operating activities	148,257	138,659
Cash flows from investing activities:
Investments in real estate	(532,527)	(253,107)
Proceeds from the sale of real estate	23,368	33,279
Capital expenditures	(34,064)	(17,330)
Restricted cash, escrow deposits and other assets	2,143	2,994
Net cash used in investing activities	(541,080)	(234,164)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	513,000	387,000
Payments on unsecured revolving credit facility	(704,000)	(247,000)
Proceeds from unsecured senior notes	347,725	0
Borrowings on unsecured term loans	200,000	100,000
Payments on unsecured term loans	(155,000)	0
Payments on secured mortgage loans	(98,453)	(76,149)
Deferred financing costs	(3,039)	(289)
Security deposits	862	145
Proceeds from issuance of general partner units	418,891	44,324
Repurchase and cancellation of general partner units	(2,425)	(1,322)
Distributions paid to general partner	(116,655)	(108,891)
Distributions paid to limited partners and redeemable noncontrolling interests	(2,724)	(1,580)
Redemption of redeemable noncontrolling interest	(491)	0
Net cash provided by financing activities	397,691	96,238
Net change in cash and cash equivalents	4,868	733
Cash and cash equivalents - beginning of period	13,070	10,413
Cash and cash equivalents - end of period	$ 17,938	$ 11,146

XML

Organization and Description of Business

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Description of Business

Organization and Description of Business

HTA, a Maryland corporation, and HTALP, a Delaware limited partnership, were incorporated or formed, as applicable, on April 20, 2006. HTA operates as a REIT and is the general partner of HTALP, which is the operating partnership. As of September 30, 2016, HTA owned a 97.0% partnership interest and other limited partners, including some of HTA’s directors, executive officers and their affiliates, owned the remaining partnership interest (including the LTIP units) in HTALP. As the sole general partner of HTALP, HTA has the full, exclusive and complete responsibility for HTALP’s day-to-day management and control. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP. As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP, issuing public equity from time to time and guaranteeing certain debts of HTALP. HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity.

HTA is one of the largest publicly-traded REITs focused on medical office buildings (“MOBs”) in the United States based on gross leasable area (“GLA”). HTA conducts substantially all of its operations through HTALP. We invest in MOBs that will serve the future of healthcare delivery, and these MOBs are primarily located on health system campuses, near university medical centers, or in core community outpatient locations. We also focus on our key markets that have certain demographic and macro-economic trends and where we can utilize our institutional property management and leasing platform to generate strong tenant relationships and operating cost efficiencies. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we: (i) seek internal growth through proactive asset management, leasing and property management oversight; (ii) target accretive acquisitions of MOBs in markets with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage. HTA has qualified to be taxed as a REIT for federal income tax purposes and intends to continue to be taxed as a REIT.

Since 2006, we have invested $4.2 billion to create a portfolio of MOBs and other healthcare assets consisting of approximately 17.6 million square feet of GLA throughout the U.S. As of September 30, 2016, approximately 97% of our portfolio, based on GLA, was located on the campuses of, or aligned with, nationally or regionally recognized healthcare systems. Our portfolio is diversified geographically across 31 states, with no state having more than 13% of our total GLA as of September 30, 2016. We are concentrated in 20 to 25 key markets that are experiencing higher economic and demographic trends, than other markets, on average, that we expect will drive demand for MOBs. Approximately 92% of our portfolio, based on GLA, is located in top 75 metropolitan statistical areas (“MSAs”) including concentrations in: Albany, Atlanta, Austin, Boston, Charleston, Columbus, Dallas, Denver, Greenville, Hartford/New Haven, Honolulu, Houston, Indianapolis, Miami, Orange County/Los Angeles, Orlando, Phoenix, Pittsburgh, Raleigh, Tampa and White Plains.

Our principal executive offices are located at 16435 North Scottsdale Road, Suite 320, Scottsdale, Arizona, 85254.

XML

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

The summary of significant accounting policies presented below is designed to assist in understanding our condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles (“GAAP”) in all material respects and have been consistently applied in preparing our accompanying condensed consolidated financial statements.

Basis of Presentation

Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2015 Annual Report on Form 10-K. There have been no significant changes to the Company’s significant accounting policies during the nine months ended September 30, 2016, except as noted below regarding the adoption of U.S. Financial Accounting Standards Board (the “FASB”) Accounting Standards Update (“ASU”) 2015-02, Amendments to the Consolidation Analysis and ASU 2015-16, Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments.

Principles of Consolidation

As of January 1, 2016, the Company adopted FASB ASU 2015-02, Amendments to the Consolidation Analysis, as described below in “Recently Issued or Adopted Accounting Pronouncements”, which simplifies consolidation accounting by reducing the number of consolidation models and changing various aspects of current GAAP, including certain consolidation criteria for VIEs. The consolidated financial statements include our accounts of those of our subsidiaries and consolidated joint venture arrangements. The portions of the operating partnership not owned by us are presented as non-controlling interests in our consolidated balance sheets and statements of operations, consolidated statements of equity, and consolidated statements of changes in partners’ capital. The portions of other joint venture arrangements not owned by us are presented as redeemable non-controlling interests in our consolidated balance sheets. In addition, as described in Note 1 - Organization and Description of Business, certain third parties have been issued limited partner units in HTALP (“OP Units”). Holders of OP Units are considered to be non-controlling interest holders in HTALP and their ownership interests are reflected as equity in the consolidated balance sheets. Further, a portion of the earnings and losses of HTALP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of common shares issued and the carrying value of the OP Units converted is recorded as a component of equity. As of September 30, 2016 and December 31, 2015, there were approximately 4.3 million and 1.9 million, respectively, of OP Units issued and outstanding.

VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. Our analysis of FASB ASU 2015-02 was concluded that our operating partnership and other joint venture arrangements are VIEs, as the limited partners in the related partnerships, although entitled to vote on certain matters, do not possess kick-out rights or substantive participating rights. Accordingly, we consolidate our interest in the operating partnership and other joint venture arrangements. Although, as we hold what is deemed a majority voting interest in the operating partnership and other joint venture arrangements, it qualifies for the exemption from providing certain of the disclosure requirements associated with investments in VIEs. We will evaluate on an ongoing basis the need to consolidate entities based on the standards set forth in GAAP as described above.

Investments in Real Estate

Depreciation expense of buildings and improvements for the three months ended September 30, 2016 and 2015 was $31.1 millionand $26.9 million, respectively. Depreciation expense of buildings and improvements for the nine months ended September 30, 2016 and 2015 was $86.6 million and $74.9 million, respectively.

Recently Issued or Adopted Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. In July 2015, the FASB deferred the effective date of ASU 2014-09 to the first interim period within annual reporting periods beginning after December 15, 2017 along with the ability to early adopt as of the original effective date. We do not anticipate early adoption and we are evaluating the impact of adopting ASU 2014-09 on our consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis. ASU 2015-02 affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. The amendments in ASU 2015-02 affect the following areas: (i) limited partnerships and similar legal entities; (ii) evaluating fees paid to a decision maker or a service provider as a variable interest; (iii) the effect of fee arrangements on the primary beneficiary determination; (iv) the effect of related parties on the primary beneficiary determination; and (v) certain investment funds. ASU 2015-02 is effective for fiscal years and for interim periods within those fiscal years, beginning after December 15, 2015 with early adoption permitted. We adopted ASU 2015-02 as of January 1, 2016. The adoption had no material impact on our interests in joint venture arrangements. Accordingly, there was no material impact on previous or current reporting periods’ consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 changes the presentation of debt issuance costs by requiring these costs related to a recognized debt liability to be presented in the consolidated balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 to include the presentation and subsequent measurement of debt issuance costs associated with line-of-credit arrangements. ASU 2015-03 and 2015-15 are effective for the fiscal years beginning after December 15, 2015, and requires retrospective application with early adoption permitted. We adopted ASU 2015-03 and 2015-15 as of December 31, 2015. As a result of the adoption, all deferred financing costs, excluding costs related to the unsecured revolving credit facility, were reclassed to debt. Unsecured revolving credit facility costs remain classified as an asset on our consolidated balance sheets and will continue to be amortized over the remaining term. The guidance requires retrospective adoption for all prior periods presented.

In September 2015, the FASB issued ASU 2015-16, Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments. ASU 2015-16 eliminates the requirement that an acquirer in a business combination has to account for measurement-period adjustments retrospectively. Instead, acquirers must recognize measurement-period adjustments during the period in which they determine the amount of the adjustment, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. ASU 2015-16 is effective for fiscal years beginning after December 15, 2015. We adopted ASU 2015-16 as of January 1, 2016. As a result of the adoption there was no material impact in the previous or current reporting periods’ consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases. ASU 2016-02 will supersede the existing guidance for lease accounting and states that companies will be required to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 requires qualitative and quantitative disclosures to supplement the amounts recorded in the financial statements so that users can understand the nature of the entity’s leasing activities, including significant judgments and changes in judgments. Within ASU 2016-02 lessor accounting remained fairly unchanged. In adopting ASU 2016-02, companies will be required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. ASU 2016-02 is effective for the fiscal years beginning after December 15, 2018 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-02 on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Compensation Accounting. ASU 2016-09 includes multiple provisions intended to simplify various aspects of accounting for share-based compensation which includes, but is not limited to, the requirement that excess tax benefits be recorded within the income statement as opposed to additional paid-in-capital and treated as an operating activity within the statement of cash flows. In addition, ASU 2016-09 allows companies to make an accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-09 on our consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). ASU 2016-13 is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2016-13 is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 includes multiple provisions intended to clarify various aspects of cash flow presentation by making eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-15 on our consolidated financial statements.

XML

Investments in Real Estate

9 Months Ended

Sep. 30, 2016

Investments [Abstract]

Investments in Real Estate

Investments in Real Estate

For the nine months ended September 30, 2016, our investments had an aggregate purchase price of $633.0 million. We incurred $2.5 million of costs attributable to these investments, which were recorded in acquisition-related expenses in the accompanying condensed consolidated statements of operations. As part of the acquisitions, we assumed mortgage loans with an aggregate fair value of $20.0 million and issued 2,650,409 OP Units with a market value at the time of issuance of $71.8 million.

The following investments were determined to be individually not significant, but significant on a collective basis. The actual revenues and earnings since the investment dates as well as the supplementary proforma information assuming these investments occurred as of the beginning of the prior periods, were not material to us. The purchase price allocation for each of our investments are preliminary and subject to change until allocations are finalized, which will be no later than 12 months from the date of acquisition. The preliminary allocations for these investments are set forth below in the aggregate for the nine months ended September 30, 2016 and 2015 (in thousands):

	Nine Months Ended September 30,
	2016			2015
Land	$	77,949		$	13,286
Building and improvements	505,138			229,386
In place leases	50,997			22,414
Below market leases	(12,790		)	(8,206		)
Above market leases	4,413			1,254
Below market leasehold interests	4,188			2,698
Above market leasehold interests	(50		)	(7,725		)
Below market debt	360			—
Interest rate swaps	(779		)	—
Net assets acquired	629,426			253,107
Other, net	3,540			1,503
Aggregate purchase price	$	632,966		$	254,610

The acquired intangible assets and liabilities referenced above had weighted average lives of the following for the nine months ended September 30, 2016 and 2015 (in years):

	Nine Months Ended September 30,
	2016	2015
Acquired intangible assets	9.1	26.8
Acquired intangible liabilities	8.3	52.4

Subsequent to September 30, 2016, we completed an investment with a purchase price of $7.2 million. The purchase price of this building was subject to certain post-closing adjustments. Due to the recent timing of the acquisition of this investment, we have not completed our initial purchase price allocation with respect to this investment and, therefore, cannot provide disclosures at this time similar to those contained in Note 3 - Investments in Real Estate to our condensed consolidated financial statements.

XML

Dispositions

9 Months Ended

Sep. 30, 2016

Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract]

Dispositions

Dispositions

During the nine months ended September 30, 2016, we completed a disposition of four senior care facilities for an aggregate gross sales price of $26.5 million, generating a gain of $4.2 million.

XML

Intangible Assets and Liabilities

9 Months Ended

Sep. 30, 2016

Identified Intangibles, Net [Abstract]

Intangible Assets and Liabilities

Intangible Assets and Liabilities

Intangible assets and liabilities consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands, except weighted average remaining amortization):

	September 30, 2016				December 31, 2015
	Balance			Weighted Average Remaining Amortization in Years	Balance			Weighted Average Remaining Amortization in Years
Assets:
In place leases	$	291,851		9.9	$	249,824		11.0
Tenant relationships	174,583			10.5	180,925			10.4
Above market leases	28,306			6.4	24,974			6.0
Below market leasehold interests	38,795			60.4	34,606			63.0
	533,535				490,329
Accumulated amortization	(246,868		)		(219,334		)
Total	$	286,667		16.1	$	270,995		16.6
Liabilities:
Below market leases	$	34,125		19.1	$	22,240		27.2
Above market leasehold interests	11,632			53.2	11,582			53.7
	45,757				33,822
Accumulated amortization	(8,829		)		(7,211		)
Total	$	36,928		29.0	$	26,611		38.0

The following is a summary of the net intangible amortization for the three and nine months ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2016			2015		2016		2015
Amortization recorded against rental income related to above or (below) market leases	$	(115	)	$	509	$	202	$	1,428
Rental expense related to above or (below) market leasehold interests	118			94		321		327
Amortization expense related to in place leases and tenant relationships	15,266			12,266		39,483		36,371

XML

Receivables and Other Assets

9 Months Ended

Sep. 30, 2016

Receivables and Other Assets [Abstract]

Receivables and Other Assets

Receivables and Other Assets

Receivables and other assets consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands):

	September 30, 2016		December 31, 2015
Tenant receivables, net	$	8,940	$	5,820
Other receivables, net	11,311		11,882
Deferred financing costs, net	4,529		5,524
Deferred leasing costs, net	19,690		17,923
Straight-line rent receivables, net	72,354		65,543
Prepaid expenses, deposits, equipment and other, net	44,013		34,584
Derivative financial instruments - interest rate swaps	—		427
Total	$	160,837	$	141,703

The following is a summary of the amortization of deferred leasing costs and financing costs for the three and nine months ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Amortization expense related to deferred leasing costs	$	1,224	$	1,013	$	3,368	$	2,941
Interest expense related to deferred financing costs (1)	331		320		994		985
(1) For the three and nine months ended September 30, 2015, amounts have been adjusted to reflect the retrospective presentation of the early adoption of ASU 2015-03 and 2015-15 as of December 31, 2015.

XML

Debt

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Debt

Debt

Debt consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands):

	September 30, 2016			December 31, 2015
Unsecured revolving credit facility	$	27,000		$	218,000
Unsecured term loans	500,000			455,000
Unsecured senior notes	950,000			600,000
Fixed rate mortgages loans	209,797			298,030
Variable rate mortgages loans	39,140			28,988
	1,725,937			1,600,018
Deferred financing costs, net	(9,853		)	(8,411		)
Discount, net	(3,486		)	(911		)
Total	$	1,712,598		$	1,590,696

Unsecured Credit Agreement

Unsecured Revolving Credit Facility

On February 11, 2015, we executed an amendment to the unsecured revolving credit and term loan facility (the “Unsecured Credit Agreement”) which increased the amount available under the unsecured revolving credit facility to $850.0 million. The actual amount of credit available to us is a function of certain loan-to-value and debt service coverage ratios set forth in the unsecured revolving credit facility. The maximum principal amount of the unsecured revolving credit facility may be increased, subject to additional financing being provided by our existing lenders or new lenders being added to the unsecured revolving credit facility. The unsecured revolving credit facility matures on January 31, 2020 and is guaranteed by HTA.

Borrowings under the unsecured revolving credit facility accrue interest at a rate equal to adjusted LIBOR, plus a margin ranging from 0.88% to 1.55% per annum based on our credit rating. We also pay a facility fee ranging from 0.13% to 0.30% per annum on the aggregate commitments under the unsecured revolving credit facility. As of September 30, 2016, the margin associated with our borrowings was 1.05% per annum and the facility fee was 0.20% per annum.

Unsecured Term Loan

As of September 30, 2016, we had a $300.0 million unsecured term loan outstanding that was guaranteed by HTA. Borrowings accrue interest at a rate equal to adjusted LIBOR, plus a margin ranging from 0.90% to 1.80% per annum based on our credit rating. The margin associated with our borrowings as of September 30, 2016 was 1.15% per annum. Including the impact of the interest rate swaps associated with our unsecured term loan, the interest rate was 1.65% per annum, based on our current credit rating. The unsecured term loan matures on January 31, 2019, and includes a one-year extension exercisable at the option of the borrower, subject to certain conditions.

$200.0 Million Unsecured Term Loan

On September 26, 2016, HTALP executed a $200.0 million unsecured term loan due on September 26, 2023. Proceeds were used to refinance our $155.0 million unsecured term loan due on July 19, 2019 and pay down existing mortgage loans. Borrowings under the unsecured term loan accrue interest at a rate equal to LIBOR, plus a margin ranging from 1.50% to 2.45% per annum based on our credit rating. The margin associated with our borrowings as of September 30, 2016 was 1.65% per annum. HTALP had interest rate swaps in place that fix the interest rate at 2.76% per annum, based on our current credit rating. As of September 30, 2016, HTALP had a $200.0 million unsecured term loan outstanding.

$300.0 Million Unsecured Senior Notes due 2021

As of September 30, 2016, HTALP had $300.0 million of unsecured senior notes outstanding that are guaranteed by HTA and that mature on July 15, 2021. The unsecured senior notes are registered under the Securities Act of 1933, as amended (the “Securities Act”), bear interest at 3.38% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.21% of the principal amount thereof, with an effective yield to maturity of 3.50% per annum.

$300.0 Million Unsecured Senior Notes due 2023

As of September 30, 2016, HTALP had $300.0 million of unsecured senior notes outstanding that are guaranteed by HTA and that mature on April 15, 2023. The unsecured senior notes are registered under the Securities Act, bear interest at 3.70% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.19% of the principal amount thereof, with an effective yield to maturity of 3.80% per annum.

$350.0 million Unsecured Senior Notes due 2026

On July 12, 2016, HTALP executed $350.0 million unsecured senior notes that are guaranteed by HTA. The unsecured senior notes are registered under the Securities Act, bear interest at 3.50% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.72% of the principal amount thereof, with an effective yield to maturity of 3.53% per annum. As of September 30, 2016, HTALP had $350.0 million of unsecured senior notes outstanding that mature on August 1, 2026.

Fixed and Variable Rate Mortgages Loans

As of September 30, 2016, HTALP and its subsidiaries had fixed and variable rate mortgages loans with interest rates ranging from 1.95% to 6.26% per annum and a weighted average interest rate of 5.03% per annum. Including the impact of the interest rate swap associated with our variable rate mortgage loans, the weighted average interest rate was 5.43% per annum.

Future Debt Maturities

The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of September 30, 2016 (in thousands):

Year	Amount
2016	$	1,433
2017	87,268
2018	4,333
2019	304,580
2020	76,796
Thereafter	1,251,527
Total	$	1,725,937

The above scheduled debt maturities do not include the extension available to us under the Unsecured Credit Agreement as discussed above.

Deferred Financing Costs

As of September 30, 2016, the future amortization of deferred financing costs is as follows (in thousands):

Year	Amount
2016	$	481
2017	1,829
2018	1,757
2019	1,762
2020	1,320
Thereafter	2,704
Total	$	9,853

We are required by the terms of our applicable debt agreements to meet various affirmative and negative covenants that we believe are customary for these types of facilities, such as limitations on the incurrence of debt by us and our subsidiaries that own unencumbered assets, limitations on the nature of HTALP’s business, and limitations on distributions by HTALP and its subsidiaries that own unencumbered assets. Our debt agreements also impose various financial covenants on us, such as a maximum ratio of total indebtedness to total asset value, a minimum ratio of EBITDA to fixed charges, a minimum tangible net worth covenant, a maximum ratio of unsecured indebtedness to unencumbered asset value, rent coverage ratios and a minimum ratio of unencumbered net operating income to unsecured interest expense. As of September 30, 2016, we believe that we were in compliance with all such financial covenants and reporting requirements. In addition, certain of our debt agreements include events of default provisions that we believe are customary for these types of facilities, including restricting HTA from making dividend distributions to its stockholders in the event HTA is in default thereunder, except to the extent necessary for HTA to maintain its REIT status.

XML

Derivative Financial Instruments

9 Months Ended

Sep. 30, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

Derivative Financial Instruments

The following table lists the derivative financial instrument assets and (liabilities) held by us as of September 30, 2016 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	50,000	LIBOR	1.39	%	$	(729	)	Swap	7/17/2019
105,000		LIBOR	1.24		(1,073		)	Swap	7/17/2019
25,480		LIBOR + 1.45%	4.98		(2,224		)	Swap	5/1/2020
6,135		LIBOR + 2.25%	4.04		(243		)	Swap	1/1/2023
4,406		LIBOR + 0.49%	3.52		(597		)	Swap	12/1/2023

The following table lists the derivative financial instrument assets and (liabilities) held by us as of December 31, 2015 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	100,000	LIBOR	0.86	%	$	(142	)	Swap	6/15/2016
50,000		LIBOR	1.39		(71		)	Swap	7/17/2019
105,000		LIBOR	1.24		427			Swap	7/17/2019
26,092		LIBOR + 1.45%	4.98		(2,157		)	Swap	5/1/2020

As of September 30, 2016 and December 31, 2015, the gross fair value of our derivative financial instruments was as follows (in thousands):

	Asset Derivatives					Liability Derivatives
		Fair Value					Fair Value
Derivatives Not Designated as Hedging Instruments:	Balance Sheet Location	September 30, 2016		December 31, 2015		Balance Sheet Location	September 30, 2016		December 31, 2015
Interest rate swaps	Receivables and other assets	$	—	$	427	Derivative financial instruments	$	4,866	$	2,370

There were no derivatives offset in our accompanying condensed consolidated balance sheets as of September 30, 2016 and December 31, 2015. As of September 30, 2016 and December 31, 2015, we had derivatives subject to enforceable master netting arrangements which allowed for net cash settlement with the respective counterparties (in thousands):

	September 30, 2016						December 31, 2015
	Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements		Net Amounts		Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements			Net Amounts
Asset derivatives	$	—	$	—	$	—	$	427	$	(427	)	$	—
Liability derivatives	4,866		—		4,866		2,370		(427		)	1,943

We have agreements with each of our interest rate swap derivative counterparties which provide that if we default on certain of our unsecured indebtedness, our counterparties could declare us in default on our interest rate swap derivative obligations resulting in an acceleration of the indebtedness. In addition, we are exposed to credit risk in the event of non-performance by our derivative counterparties. We believe we mitigate the credit risk by entering into agreements with credit-worthy counterparties. We record counterparty credit risk valuation adjustments on interest rate swap derivative assets in order to properly reflect the credit quality of the counterparty. In addition, our fair value of interest rate swap derivative liabilities is adjusted to reflect the impact of our credit quality. As of September 30, 2016, there have been no termination events or events of default related to our interest rate swaps.

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Litigation

We are not presently subject to any material litigation nor, to our knowledge, is any material litigation threatened against us, which if determined unfavorably to us, would have a material effect on our condensed consolidated financial position, results of operations or cash flows.

Environmental Matters

We follow the policy of monitoring our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our condensed consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability at our properties that we believe would require additional disclosure or the recording of a loss contingency.

Other

Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business. In our opinion, these matters are not expected to have a material effect on our condensed consolidated financial position, results of operations or cash flows.

XML

Stockholders' Equity and Partners' Capital

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Stockholders' Equity and Partners' Capital

Stockholders’ Equity and Partners’ Capital

HTALP’s partnership agreement provides that it will distribute cash flow from operations and net sale proceeds to its partners in accordance with their overall ownership interests at such times and in such amounts as the general partner determines. Dividend distributions are made such that a holder of one partnership unit in HTALP will receive distributions from HTALP in an amount equal to the dividend distributions paid to the holder of one share of HTA’s common stock. In addition, for each share of common stock issued or redeemed by HTA, HTALP issues or redeems a corresponding number of partnership units.

During the nine months ended September 30, 2016, HTA issued $492.5 million of equity at an average price of $29.33 per share.

Common Stock Offerings

In January 2016, HTA entered into a new equity distribution agreement with respect to its at-the-market (“ATM”) offering program of common stock with an aggregate sales amount of up to $300.0 million. During the nine months ended September 30, 2016, HTA issued and sold 4,418,571 shares of its common stock for $122.9 million at an average price of $27.82 per share, and as of September 30, 2016, $177.1 million remained available for issuance under the ATM.

During the nine months ended September 30, 2016, HTA completed underwritten public offerings with a cumulative 9,720,000 shares of common stock for $297.8 million at an average price of $30.64 per share.

Common Unit Offerings

During the nine months ended September 30, 2016, HTA issued 2,650,409 OP Units in HTALP, respectively, for approximately $71.8 million in connection with acquisition transactions.

Common Stock Dividends

See our accompanying condensed consolidated statements of operations for the dividends declared during the three and nine months ended September 30, 2016 and 2015. On October 25, 2016, HTA declared a quarterly cash dividend of $0.30 per share to be paid on January 10, 2017 to stockholders of record of its common stock on January 3, 2017.

Incentive Plan

HTA’s Amended and Restated 2006 Incentive Plan (the “Plan”) permits the grant of incentive awards to our employees, officers, non-employee directors and consultants as selected by our Board of Directors. The Plan authorizes the granting of awards in any of the following forms: options; stock appreciation rights; restricted stock; restricted or deferred stock units; performance awards; dividend equivalents; other stock-based awards, including units in HTALP; and cash-based awards. Subject to adjustment as provided in the Plan, the aggregate number of awards reserved and available for issuance under the Plan is 5,000,000. As of September 30, 2016, there were 1,921,610 awards available for grant under the Plan.

LTIP Units

Awards under the LTIP consist of Series C units inHTALPand were subject to the achievement of certain performance and market conditions in order to vest. Once vested, the Series C units were converted into common units of HTALP, which may be converted into shares of HTA’s common stock. The LTIP awards were fully expensed in 2013, except for225,000units that were forfeited in 2015.

Restricted Common Stock

For the three and nine months ended September 30, 2016, we recognized compensation expense of $2.1 million and $5.1 million, respectively. For the three and nine months ended September 30, 2015, we recognized compensation expense of $1.4 million and $4.5 million, respectively. Compensation expense for the three and nine months ended September 30, 2016 and 2015 were recorded in general and administrative expenses in the accompanying condensed consolidated statements of operations.

As of September 30, 2016, there was $10.2 million of unrecognized compensation expense net of estimated forfeitures, which will be recognized over a remaining weighted average period of 2.0 years.

The following is a summary of our restricted common stock activity during the nine months ended September 30, 2016 and 2015 (in thousands, except weighted average grant date fair value):

	September 30, 2016				September 30, 2015
	Restricted Common Stock		Weighted Average Grant Date Fair Value		Restricted Common Stock		Weighted Average Grant Date Fair Value
Beginning balance	487,850		$	23.13	463,050		$	20.90
Granted	417,110		29.82		221,076		26.57
Vested	(236,749	)	23.27		(135,213	)	21.89
Forfeited	(24,391	)	25.93		(21,378	)	22.70
Ending balance	643,820		$	27.35	527,535		$	22.88

XML

Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Financial Instruments Reported at Fair Value - Recurring

The table below presents our assets and liabilities measured at fair value on a recurring basis as of September 30, 2016, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	—	$	—	$	—
Liabilities:
Derivative financial instruments	$	—	$	4,866	$	—	$	4,866

The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2015, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	427	$	—	$	427
Liabilities:
Derivative financial instruments	$	—	$	2,370	$	—	$	2,370

Financial Instruments Reported at Fair Value - Non-Recurring

As of September 30, 2016, there were noassets measured at fair value on a non-recurring basis. The table below presents our assets measured at fair value on a non-recurring basis as of December 31, 2015, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
MOB (1)	$	—	$	547	$	—	$	547
(1) During the year ended December 31, 2015, we recognized a $0.9 million impairment charge to the carrying value of an MOB. The estimated fair value as of December 31, 2015 was based upon a pending sales agreement pertaining to this MOB.

There have been no transfers of assets or liabilities between levels. We will record any such transfers at the end of the reporting period in which a change of event occurs that results in a transfer. Although we have determined that the majority of the inputs used to value our interest rate swap derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. However, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our interest rate swap derivative positions and have determined that the credit valuation adjustments are not significant to their overall valuation. As a result, we have determined that our interest rate swap derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Financial Instruments Disclosed at Fair Value

We consider the carrying values of cash and cash equivalents, tenant and other receivables, restricted cash and escrow deposits and accounts payable, and accrued liabilities, to approximate fair value for these financial instruments because of the short period of time between origination of the instruments and their expected realization. All of these financial instruments are considered Level 2.

The fair value of debt is estimated using borrowing rates available to us with similar terms and maturities, which is considered a Level 2 input. As of September 30, 2016, the fair value of the debt was $1,781.6 million compared to the carrying value of $1,712.6 million. As of December 31, 2015, the fair value of the debt was $1,619.7 million compared to the carrying value of $1,590.7 million.

XML

Per Share Data of HTA

9 Months Ended

Sep. 30, 2016

HTA, Inc.

Earnings Per Share

Per Share Data of HTA

Per Share Data of HTA

HTA includes unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents as “participating securities” pursuant to the two-class method. The resulting classes are our common stock and restricted stock. For the three and nine months ended September 30, 2016 and 2015, all of HTA’s earnings were distributed and the calculated earnings per share amount would be the same for all classes.

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three and nine months ended September 30, 2016 and 2015 (in thousands, except per share data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Numerator:
Net income	$	6,639		$	6,554		$	30,191		$	22,984
Net income attributable to noncontrolling interests	(212		)	(91		)	(830		)	(425		)
Net income attributable to common stockholders	$	6,427		$	6,463		$	29,361		$	22,559
Denominator:
Weighted average shares outstanding - basic	138,807			126,863			134,905			125,750
Dilutive shares	4,331			1,930			3,409			1,930
Weighted average shares outstanding - diluted	143,138			128,793			138,314			127,680
Earnings per common share - basic
Net income attributable to common stockholders	$	0.05		$	0.05		$	0.22		$	0.18
Earnings per common share - diluted
Net income attributable to common stockholders	$	0.04		$	0.05		$	0.21		$	0.18

XML

Per Unit Data of HTALP

9 Months Ended

Sep. 30, 2016

Healthcare Trust of America Holdings, LP (HTALP)

Earnings Per Share

Per Unit Data of HTALP

Per Unit Data of HTALP

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and nine months ended September 30, 2016 and 2015 (in thousands, except per unit data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Numerator:
Net income	$	6,639		$	6,554		$	30,191		$	22,984
Net income attributable to noncontrolling interests	(1		)	(20		)	(28		)	(77		)
Net income attributable to common unitholders	$	6,638		$	6,534		$	30,163		$	22,907
Denominator:
Weighted average units outstanding - basic	143,137			128,793			138,314			127,781
Dilutive units	—			—			—			—
Weighted average units outstanding - diluted	143,137			128,793			138,314			127,781
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.05		$	0.05		$	0.22		$	0.18
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.05		$	0.05		$	0.22		$	0.18

XML

Supplemental Cash Flow Information

9 Months Ended

Sep. 30, 2016

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

Supplemental Cash Flow Information

The following is the supplemental cash flow information for the nine months ended September 30, 2016 and 2015 (in thousands):

	Nine Months Ended September 30,
	2016		2015
Supplemental Disclosure of Cash Flow Information:
Interest paid	$	39,321	$	39,570
Income taxes paid	934		790
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accrued capital expenditures	$	2,868	$	1,833
Debt and interest rate swaps assumed in connection with an acquisition	21,156		—
Dividend distributions declared, but not paid	43,530		37,712
Issuance of operating partnership units in connection with an acquisition	71,754		—
Note receivable included in the consideration of a disposition	3,000		—
Redeemable noncontrolling interest assumed in connection with an acquisition	5,449		—
Redemption of noncontrolling interests	5,709		—

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Basis of Presentation

Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2015 Annual Report on Form 10-K. There have been no significant changes to the Company’s significant accounting policies during the nine months ended September 30, 2016, except as noted below regarding the adoption of U.S. Financial Accounting Standards Board (the “FASB”) Accounting Standards Update (“ASU”) 2015-02, Amendments to the Consolidation Analysis and ASU 2015-16, Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments.

Principles of Consolidation

As of January 1, 2016, the Company adopted FASB ASU 2015-02, Amendments to the Consolidation Analysis, as described below in “Recently Issued or Adopted Accounting Pronouncements”, which simplifies consolidation accounting by reducing the number of consolidation models and changing various aspects of current GAAP, including certain consolidation criteria for VIEs. The consolidated financial statements include our accounts of those of our subsidiaries and consolidated joint venture arrangements. The portions of the operating partnership not owned by us are presented as non-controlling interests in our consolidated balance sheets and statements of operations, consolidated statements of equity, and consolidated statements of changes in partners’ capital. The portions of other joint venture arrangements not owned by us are presented as redeemable non-controlling interests in our consolidated balance sheets. In addition, as described in Note 1 - Organization and Description of Business, certain third parties have been issued limited partner units in HTALP (“OP Units”). Holders of OP Units are considered to be non-controlling interest holders in HTALP and their ownership interests are reflected as equity in the consolidated balance sheets. Further, a portion of the earnings and losses of HTALP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of common shares issued and the carrying value of the OP Units converted is recorded as a component of equity. As of September 30, 2016 and December 31, 2015, there were approximately 4.3 million and 1.9 million, respectively, of OP Units issued and outstanding.

VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. Our analysis of FASB ASU 2015-02 was concluded that our operating partnership and other joint venture arrangements are VIEs, as the limited partners in the related partnerships, although entitled to vote on certain matters, do not possess kick-out rights or substantive participating rights. Accordingly, we consolidate our interest in the operating partnership and other joint venture arrangements. Although, as we hold what is deemed a majority voting interest in the operating partnership and other joint venture arrangements, it qualifies for the exemption from providing certain of the disclosure requirements associated with investments in VIEs. We will evaluate on an ongoing basis the need to consolidate entities based on the standards set forth in GAAP as described above.

Recently Issued or Adopted Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. In July 2015, the FASB deferred the effective date of ASU 2014-09 to the first interim period within annual reporting periods beginning after December 15, 2017 along with the ability to early adopt as of the original effective date. We do not anticipate early adoption and we are evaluating the impact of adopting ASU 2014-09 on our consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis. ASU 2015-02 affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. The amendments in ASU 2015-02 affect the following areas: (i) limited partnerships and similar legal entities; (ii) evaluating fees paid to a decision maker or a service provider as a variable interest; (iii) the effect of fee arrangements on the primary beneficiary determination; (iv) the effect of related parties on the primary beneficiary determination; and (v) certain investment funds. ASU 2015-02 is effective for fiscal years and for interim periods within those fiscal years, beginning after December 15, 2015 with early adoption permitted. We adopted ASU 2015-02 as of January 1, 2016. The adoption had no material impact on our interests in joint venture arrangements. Accordingly, there was no material impact on previous or current reporting periods’ consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 changes the presentation of debt issuance costs by requiring these costs related to a recognized debt liability to be presented in the consolidated balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 to include the presentation and subsequent measurement of debt issuance costs associated with line-of-credit arrangements. ASU 2015-03 and 2015-15 are effective for the fiscal years beginning after December 15, 2015, and requires retrospective application with early adoption permitted. We adopted ASU 2015-03 and 2015-15 as of December 31, 2015. As a result of the adoption, all deferred financing costs, excluding costs related to the unsecured revolving credit facility, were reclassed to debt. Unsecured revolving credit facility costs remain classified as an asset on our consolidated balance sheets and will continue to be amortized over the remaining term. The guidance requires retrospective adoption for all prior periods presented.

In September 2015, the FASB issued ASU 2015-16, Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments. ASU 2015-16 eliminates the requirement that an acquirer in a business combination has to account for measurement-period adjustments retrospectively. Instead, acquirers must recognize measurement-period adjustments during the period in which they determine the amount of the adjustment, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. ASU 2015-16 is effective for fiscal years beginning after December 15, 2015. We adopted ASU 2015-16 as of January 1, 2016. As a result of the adoption there was no material impact in the previous or current reporting periods’ consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases. ASU 2016-02 will supersede the existing guidance for lease accounting and states that companies will be required to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 requires qualitative and quantitative disclosures to supplement the amounts recorded in the financial statements so that users can understand the nature of the entity’s leasing activities, including significant judgments and changes in judgments. Within ASU 2016-02 lessor accounting remained fairly unchanged. In adopting ASU 2016-02, companies will be required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. ASU 2016-02 is effective for the fiscal years beginning after December 15, 2018 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-02 on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Compensation Accounting. ASU 2016-09 includes multiple provisions intended to simplify various aspects of accounting for share-based compensation which includes, but is not limited to, the requirement that excess tax benefits be recorded within the income statement as opposed to additional paid-in-capital and treated as an operating activity within the statement of cash flows. In addition, ASU 2016-09 allows companies to make an accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-09 on our consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). ASU 2016-13 is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2016-13 is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 includes multiple provisions intended to clarify various aspects of cash flow presentation by making eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2016-15 on our consolidated financial statements.

XML

Investments in Real Estate (Tables)

9 Months Ended

Sep. 30, 2016

Investments [Abstract]

Schedule of Purchase Price Allocation

The following investments were determined to be individually not significant, but significant on a collective basis. The actual revenues and earnings since the investment dates as well as the supplementary proforma information assuming these investments occurred as of the beginning of the prior periods, were not material to us. The purchase price allocation for each of our investments are preliminary and subject to change until allocations are finalized, which will be no later than 12 months from the date of acquisition. The preliminary allocations for these investments are set forth below in the aggregate for the nine months ended September 30, 2016 and 2015 (in thousands):

	Nine Months Ended September 30,
	2016			2015
Land	$	77,949		$	13,286
Building and improvements	505,138			229,386
In place leases	50,997			22,414
Below market leases	(12,790		)	(8,206		)
Above market leases	4,413			1,254
Below market leasehold interests	4,188			2,698
Above market leasehold interests	(50		)	(7,725		)
Below market debt	360			—
Interest rate swaps	(779		)	—
Net assets acquired	629,426			253,107
Other, net	3,540			1,503
Aggregate purchase price	$	632,966		$	254,610

Schedule of Weighted Average Lives of Acquired Intangible Assets and Liabilities

The acquired intangible assets and liabilities referenced above had weighted average lives of the following for the nine months ended September 30, 2016 and 2015 (in years):

	Nine Months Ended September 30,
	2016	2015
Acquired intangible assets	9.1	26.8
Acquired intangible liabilities	8.3	52.4

XML

Intangible Assets and Liabilities (Tables)

9 Months Ended

Sep. 30, 2016

Identified Intangibles, Net [Abstract]

Schedule of Intangible Assets and Liabilities

Intangible assets and liabilities consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands, except weighted average remaining amortization):

	September 30, 2016				December 31, 2015
	Balance			Weighted Average Remaining Amortization in Years	Balance			Weighted Average Remaining Amortization in Years
Assets:
In place leases	$	291,851		9.9	$	249,824		11.0
Tenant relationships	174,583			10.5	180,925			10.4
Above market leases	28,306			6.4	24,974			6.0
Below market leasehold interests	38,795			60.4	34,606			63.0
	533,535				490,329
Accumulated amortization	(246,868		)		(219,334		)
Total	$	286,667		16.1	$	270,995		16.6
Liabilities:
Below market leases	$	34,125		19.1	$	22,240		27.2
Above market leasehold interests	11,632			53.2	11,582			53.7
	45,757				33,822
Accumulated amortization	(8,829		)		(7,211		)
Total	$	36,928		29.0	$	26,611		38.0

Summary of Net Intangible Amortization

The following is a summary of the net intangible amortization for the three and nine months ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2016			2015		2016		2015
Amortization recorded against rental income related to above or (below) market leases	$	(115	)	$	509	$	202	$	1,428
Rental expense related to above or (below) market leasehold interests	118			94		321		327
Amortization expense related to in place leases and tenant relationships	15,266			12,266		39,483		36,371

XML

Receivables and Other Assets (Tables)

9 Months Ended

Sep. 30, 2016

Receivables and Other Assets [Abstract]

Schedule of Receivables and Other Assets

Receivables and other assets consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands):

	September 30, 2016		December 31, 2015
Tenant receivables, net	$	8,940	$	5,820
Other receivables, net	11,311		11,882
Deferred financing costs, net	4,529		5,524
Deferred leasing costs, net	19,690		17,923
Straight-line rent receivables, net	72,354		65,543
Prepaid expenses, deposits, equipment and other, net	44,013		34,584
Derivative financial instruments - interest rate swaps	—		427
Total	$	160,837	$	141,703

Summary of Amortization of Deferred Leasing Costs and Deferred Financing Costs

The following is a summary of the amortization of deferred leasing costs and financing costs for the three and nine months ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Amortization expense related to deferred leasing costs	$	1,224	$	1,013	$	3,368	$	2,941
Interest expense related to deferred financing costs (1)	331		320		994		985
(1) For the three and nine months ended September 30, 2015, amounts have been adjusted to reflect the retrospective presentation of the early adoption of ASU 2015-03 and 2015-15 as of December 31, 2015.

XML

Debt (Tables)

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Schedule of Debt

Debt consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands):

	September 30, 2016			December 31, 2015
Unsecured revolving credit facility	$	27,000		$	218,000
Unsecured term loans	500,000			455,000
Unsecured senior notes	950,000			600,000
Fixed rate mortgages loans	209,797			298,030
Variable rate mortgages loans	39,140			28,988
	1,725,937			1,600,018
Deferred financing costs, net	(9,853		)	(8,411		)
Discount, net	(3,486		)	(911		)
Total	$	1,712,598		$	1,590,696

Summary of Debt Maturities and Scheduled Principal Debt Repayments

The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of September 30, 2016 (in thousands):

Year	Amount
2016	$	1,433
2017	87,268
2018	4,333
2019	304,580
2020	76,796
Thereafter	1,251,527
Total	$	1,725,937

Schedule of Amortization of Deferred Financing Costs

As of September 30, 2016, the future amortization of deferred financing costs is as follows (in thousands):

Year	Amount
2016	$	481
2017	1,829
2018	1,757
2019	1,762
2020	1,320
Thereafter	2,704
Total	$	9,853

XML

Derivative Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instrument Assets and (Liabilities) Held

The following table lists the derivative financial instrument assets and (liabilities) held by us as of September 30, 2016 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	50,000	LIBOR	1.39	%	$	(729	)	Swap	7/17/2019
105,000		LIBOR	1.24		(1,073		)	Swap	7/17/2019
25,480		LIBOR + 1.45%	4.98		(2,224		)	Swap	5/1/2020
6,135		LIBOR + 2.25%	4.04		(243		)	Swap	1/1/2023
4,406		LIBOR + 0.49%	3.52		(597		)	Swap	12/1/2023

The following table lists the derivative financial instrument assets and (liabilities) held by us as of December 31, 2015 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	100,000	LIBOR	0.86	%	$	(142	)	Swap	6/15/2016
50,000		LIBOR	1.39		(71		)	Swap	7/17/2019
105,000		LIBOR	1.24		427			Swap	7/17/2019
26,092		LIBOR + 1.45%	4.98		(2,157		)	Swap	5/1/2020

Gross Fair Value of Derivative Financial Instruments

As of September 30, 2016 and December 31, 2015, the gross fair value of our derivative financial instruments was as follows (in thousands):

	Asset Derivatives					Liability Derivatives
		Fair Value					Fair Value
Derivatives Not Designated as Hedging Instruments:	Balance Sheet Location	September 30, 2016		December 31, 2015		Balance Sheet Location	September 30, 2016		December 31, 2015
Interest rate swaps	Receivables and other assets	$	—	$	427	Derivative financial instruments	$	4,866	$	2,370

Schedule of Derivative Liabilities Subject to Master Netting Arrangements

As of September 30, 2016 and December 31, 2015, we had derivatives subject to enforceable master netting arrangements which allowed for net cash settlement with the respective counterparties (in thousands):

	September 30, 2016						December 31, 2015
	Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements		Net Amounts		Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements			Net Amounts
Asset derivatives	$	—	$	—	$	—	$	427	$	(427	)	$	—
Liability derivatives	4,866		—		4,866		2,370		(427		)	1,943

Schedule of Derivative Assets Subject to Master Netting Arrangements

As of September 30, 2016 and December 31, 2015, we had derivatives subject to enforceable master netting arrangements which allowed for net cash settlement with the respective counterparties (in thousands):

	September 30, 2016						December 31, 2015
	Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements		Net Amounts		Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements			Net Amounts
Asset derivatives	$	—	$	—	$	—	$	427	$	(427	)	$	—
Liability derivatives	4,866		—		4,866		2,370		(427		)	1,943

XML

Stockholders' Equity and Partners' Capital (Tables)

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Schedule of Restricted Common Stock Activity

The following is a summary of our restricted common stock activity during the nine months ended September 30, 2016 and 2015 (in thousands, except weighted average grant date fair value):

	September 30, 2016				September 30, 2015
	Restricted Common Stock		Weighted Average Grant Date Fair Value		Restricted Common Stock		Weighted Average Grant Date Fair Value
Beginning balance	487,850		$	23.13	463,050		$	20.90
Granted	417,110		29.82		221,076		26.57
Vested	(236,749	)	23.27		(135,213	)	21.89
Forfeited	(24,391	)	25.93		(21,378	)	22.70
Ending balance	643,820		$	27.35	527,535		$	22.88

XML

Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The table below presents our assets and liabilities measured at fair value on a recurring basis as of September 30, 2016, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	—	$	—	$	—
Liabilities:
Derivative financial instruments	$	—	$	4,866	$	—	$	4,866

The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2015, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	427	$	—	$	427
Liabilities:
Derivative financial instruments	$	—	$	2,370	$	—	$	2,370

Schedule of Fair Value, Assets Measured on Non-Recurring Basis

The table below presents our assets measured at fair value on a non-recurring basis as of December 31, 2015, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
MOB (1)	$	—	$	547	$	—	$	547
(1) During the year ended December 31, 2015, we recognized a $0.9 million impairment charge to the carrying value of an MOB. The estimated fair value as of December 31, 2015 was based upon a pending sales agreement pertaining to this MOB.

XML

Per Share Data of HTA (Tables)

9 Months Ended

Sep. 30, 2016

HTA, Inc.

Earnings Per Share

Schedule of Earnings Per Share, Basic and Diluted

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three and nine months ended September 30, 2016 and 2015 (in thousands, except per share data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Numerator:
Net income	$	6,639		$	6,554		$	30,191		$	22,984
Net income attributable to noncontrolling interests	(212		)	(91		)	(830		)	(425		)
Net income attributable to common stockholders	$	6,427		$	6,463		$	29,361		$	22,559
Denominator:
Weighted average shares outstanding - basic	138,807			126,863			134,905			125,750
Dilutive shares	4,331			1,930			3,409			1,930
Weighted average shares outstanding - diluted	143,138			128,793			138,314			127,680
Earnings per common share - basic
Net income attributable to common stockholders	$	0.05		$	0.05		$	0.22		$	0.18
Earnings per common share - diluted
Net income attributable to common stockholders	$	0.04		$	0.05		$	0.21		$	0.18

XML

Per Unit Data of HTALP (Tables)

9 Months Ended

Sep. 30, 2016

Healthcare Trust of America Holdings, LP (HTALP)

Earnings Per Share

Schedule of Earnings Per Unit, Basic and Diluted

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and nine months ended September 30, 2016 and 2015 (in thousands, except per unit data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Numerator:
Net income	$	6,639		$	6,554		$	30,191		$	22,984
Net income attributable to noncontrolling interests	(1		)	(20		)	(28		)	(77		)
Net income attributable to common unitholders	$	6,638		$	6,534		$	30,163		$	22,907
Denominator:
Weighted average units outstanding - basic	143,137			128,793			138,314			127,781
Dilutive units	—			—			—			—
Weighted average units outstanding - diluted	143,137			128,793			138,314			127,781
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.05		$	0.05		$	0.22		$	0.18
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.05		$	0.05		$	0.22		$	0.18

XML

Supplemental Cash Flow Information (Tables)

9 Months Ended

Sep. 30, 2016

Supplemental Cash Flow Elements [Abstract]

Schedule of Supplemental Cash Flow Information

The following is the supplemental cash flow information for the nine months ended September 30, 2016 and 2015 (in thousands):

	Nine Months Ended September 30,
	2016		2015
Supplemental Disclosure of Cash Flow Information:
Interest paid	$	39,321	$	39,570
Income taxes paid	934		790
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accrued capital expenditures	$	2,868	$	1,833
Debt and interest rate swaps assumed in connection with an acquisition	21,156		—
Dividend distributions declared, but not paid	43,530		37,712
Issuance of operating partnership units in connection with an acquisition	71,754		—
Note receivable included in the consideration of a disposition	3,000		—
Redeemable noncontrolling interest assumed in connection with an acquisition	5,449		—
Redemption of noncontrolling interests	5,709		—

XML

Organization and Description of Business (Details) ft² in Millions, $ in Billions	9 Months Ended
	Sep. 30, 2016 USD ($) ft² market States
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General partnership interest (as a percent)	97.00%
Purchased property inception to current date | $	$ 4.2
Gross leasable area of real estate in portfolio (in square feet) | ft²	17.6
Concentration Risk [Line Items]
Percentage of gross leasable area on-campus/aligned	97.00%
Number of states in which the Company operates | States	31
Maximum state gross leasable area (as a percent)	13.00%
Percentage of gross leasable area located in the top 75 Metro statistical areas	92.00%
Minimum
Concentration Risk [Line Items]
Number of markets where the Company is concentrated	20
Maximum
Concentration Risk [Line Items]
Number of markets where the Company is concentrated	25

XML

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Building Improvements
Partners' Capital Notes [Abstract]
Depreciation expense	$ 31.1	$ 26.9	$ 86.6	$ 74.9
Healthcare Trust of America Holdings, LP (HTALP)
Partners' Capital Notes [Abstract]
Limited partner's capital, units issued	4,323,095		4,323,095		1,929,942
Limited partner's capital, units outstanding	4,323,095		4,323,095		1,929,942

XML

Investments in Real Estate - Acquisitions (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Oct. 26, 2016	Sep. 30, 2016	Sep. 30, 2015
Investments [Abstract]
Closing costs		$ 2,500
Mortgage loans assumed		20,000
Business Acquisition [Line Items]
Land		77,949	$ 13,286
Building and improvements		505,138	229,386
In place leases		50,997	22,414
Below market leases		(12,790)	(8,206)
Above market leases		4,413	1,254
Below market leasehold interests		4,188	2,698
Above market leasehold interests		(50)	(7,725)
Below market debt		360	0
Interest rate swaps		(779)	0
Net assets acquired		629,426	253,107
Other, net		3,540	1,503
Aggregate purchase price		$ 632,966	$ 254,610
Subsequent Event
Business Acquisition [Line Items]
Aggregate purchase price	$ 7,200
Partnership Units
Business Acquisition [Line Items]
Number of operating partnership units issued in acquisition (shares)		2,650,409
Market value of operating partnership units issued in acquisition		$ 71,800

XML

Investments in Real Estate - Weighted Average Lives (Details)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Investments [Abstract]
Acquired intangible assets	9 years 1 month 6 days	26 years 9 months 21 days
Acquired intangible liabilities	8 years 3 months 18 days	52 years 5 months 8 days

XML

Dispositions (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) facility	Sep. 30, 2015 USD ($)
Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract]
Number of senior care facilities disposed (in facilities) | facility			4
Aggregate gross sales price of facilities disposed			$ 26,500
Gain from sale of dispositions of properties	$ 0	$ 152	$ 4,212	$ 152

XML

Intangible Assets and Liabilities - Summary of Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Assets:
Gross	$ 533,535	$ 490,329
Accumulated amortization	(246,868)	(219,334)
Total	$ 286,667	$ 270,995
Weighted Average Remaining Amortization in Years	16 years 1 month 6 days	16 years 7 months 6 days
Liabilities:
Gross	$ 45,757	$ 33,822
Accumulated amortization	(8,829)	(7,211)
Total	$ 36,928	$ 26,611
Weighted Average Remaining Amortization in Years	29 years	38 years
Below market leases
Liabilities:
Gross	$ 34,125	$ 22,240
Weighted Average Remaining Amortization in Years	19 years 1 month 6 days	27 years 2 months 12 days
Above market leasehold interests
Liabilities:
Gross	$ 11,632	$ 11,582
Weighted Average Remaining Amortization in Years	53 years 2 months 12 days	53 years 8 months 12 days
In place leases
Assets:
Gross	$ 291,851	$ 249,824
Weighted Average Remaining Amortization in Years	9 years 10 months 24 days	11 years
Tenant relationships
Assets:
Gross	$ 174,583	$ 180,925
Weighted Average Remaining Amortization in Years	10 years 6 months	10 years 4 months 24 days
Above market leases
Assets:
Gross	$ 28,306	$ 24,974
Weighted Average Remaining Amortization in Years	6 years 4 months 24 days	6 years
Below market leasehold interests
Assets:
Gross	$ 38,795	$ 34,606
Weighted Average Remaining Amortization in Years	60 years 4 months 24 days	63 years

XML

Intangible Assets and Liabilities - Summary of Intangible Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Amortization recorded against rental income related to above or (below) market leases
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items]
Amortization of intangible assets and liabilities	$ (115)	$ 509	$ 202	$ 1,428
Rental expense related to above or (below) market leasehold interests
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items]
Amortization of intangible assets and liabilities	118	94	321	327
Amortization expense related to in place leases and tenant relationships
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items]
Amortization of intangible assets and liabilities	$ 15,266	$ 12,266	$ 39,483	$ 36,371

XML

Receivables and Other Assets - Schedule of Receivables and Other Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Receivables and Other Assets [Abstract]
Tenant receivables, net	$ 8,940	$ 5,820
Other receivables, net	11,311	11,882
Deferred financing costs, net	4,529	5,524
Deferred leasing costs, net	19,690	17,923
Straight-line rent receivables, net	72,354	65,543
Prepaid expenses, deposits, equipment and other, net	44,013	34,584
Derivative financial instruments - interest rate swaps	0	427
Total	$ 160,837	$ 141,703

XML

Receivables and Other Assets - Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Receivables and Other Assets [Abstract]
Amortization expense related to deferred leasing costs	$ 1,224	$ 1,013	$ 3,368	$ 2,941
Interest expense related to deferred financing costs	$ 331	$ 320	$ 994	$ 985

XML

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument
Total debt, gross	$ 1,725,937	$ 1,600,018
Deferred financing costs, net	(9,853)	(8,411)
Discount, net	(3,486)	(911)
Total	1,712,598	1,590,696
Unsecured term loans
Debt Instrument
Total debt, gross	500,000	455,000
Unsecured senior notes
Debt Instrument
Total debt, gross	950,000	600,000
Mortgages | Fixed rate mortgages loans
Debt Instrument
Total debt, gross	209,797	298,030
Mortgages | Variable rate mortgages loans
Debt Instrument
Total debt, gross	39,140	28,988
Unsecured revolving credit facility
Debt Instrument
Line of credit facility, amount outstanding	$ 27,000	$ 218,000

XML

Debt - Principal Maturity Schedule (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
2016	$ 1,433
2017	87,268
2018	4,333
2019	304,580
2020	76,796
Thereafter	1,251,527
Total	$ 1,725,937	$ 1,600,018

XML

Debt - Amortization of Deferred Financing Costs (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
2016	$ 481
2017	1,829
2018	1,757
2019	1,762
2020	1,320
Thereafter	2,704
Total	$ 9,853	$ 8,411

XML

Debt - Textuals (Details) - USD ($)		9 Months Ended
	Feb. 11, 2015	Sep. 30, 2016	Sep. 26, 2016	Sep. 25, 2016	Jul. 12, 2016	Dec. 31, 2015
Debt Instrument
Outstanding amount		$ 1,725,937,000				$ 1,600,018,000
Unsecured term loans
Debt Instrument
Outstanding amount		$ 500,000,000				455,000,000
Unsecured term loans | $300.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)		1.15%
Outstanding amount		$ 300,000,000
Unsecured credit agreement, extension option period (in years)		1 year
Weighted average interest rate with interest rate swap impact (as a percent)		1.65%
Unsecured term loans | $200.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)		1.65%
Debt instrument, face amount		$ 200,000,000	$ 200,000,000	$ 155,000,000
Weighted average interest rate with interest rate swap impact (as a percent)		2.76%
Unsecured senior notes
Debt Instrument
Outstanding amount		$ 950,000,000				$ 600,000,000
Unsecured senior notes | $300.0 Million Unsecured Senior Notes due 2021
Debt Instrument
Debt instrument, face amount		$ 300,000,000
Debt instrument, stated interest rate (as a percent)		3.38%
Debt instrument, percentage of principal amount received (as a percent)		99.21%
Debt instrument, effective interest rate (as a percent)		3.50%
Unsecured senior notes | $300.0 Million Unsecured Senior Notes due 2023
Debt Instrument
Debt instrument, face amount		$ 300,000,000
Debt instrument, stated interest rate (as a percent)		3.70%
Debt instrument, percentage of principal amount received (as a percent)		99.19%
Debt instrument, effective interest rate (as a percent)		3.80%
Unsecured senior notes | $350.0 Million Unsecured Senior Notes due 2026
Debt Instrument
Debt instrument, face amount					$ 350,000,000
Debt instrument, stated interest rate (as a percent)		3.50%
Debt instrument, percentage of principal amount received (as a percent)		99.72%
Debt instrument, effective interest rate (as a percent)		3.53%
Mortgages
Debt Instrument
Weighted average interest rate with interest rate swap impact (as a percent)		5.43%
Weighted average interest rate (as a percent)		5.03%
Minimum | Unsecured term loans | $300.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)		0.90%
Minimum | Unsecured term loans | $200.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)		1.50%
Minimum | Mortgages
Debt Instrument
Debt instrument, effective interest rate (as a percent)		1.95%
Maximum | Unsecured term loans | $300.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)		1.80%
Maximum | Unsecured term loans | $200.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)		2.45%
Maximum | Mortgages
Debt Instrument
Debt instrument, effective interest rate (as a percent)		6.26%
Unsecured revolving credit facility
Debt Instrument
Line of credit facility, borrowing capacity	$ 850,000,000
Basis spread on variable rate (as a percent)		1.05%
Line of credit facility, commitment fee (as a percent)		0.20%
Unsecured revolving credit facility | Minimum
Debt Instrument
Basis spread on variable rate (as a percent)	0.88%
Line of credit facility, commitment fee (as a percent)	0.13%
Unsecured revolving credit facility | Maximum
Debt Instrument
Basis spread on variable rate (as a percent)	1.55%
Line of credit facility, commitment fee (as a percent)	0.30%

XML

Derivative Financial Instruments - Table of Derivative Financial Instruments (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Swap at 1.39%
Derivative
Notional Amount	$ 50,000	$ 50,000
Index	LIBOR	LIBOR
Rate (as a percent)	1.39%	1.39%
Derivative liabilities	$ (729)	$ (71)
Swap at 0.86%
Derivative
Notional Amount		$ 100,000
Index		LIBOR
Rate (as a percent)		0.86%
Derivative liabilities		$ (142)
Swap at 1.24%
Derivative
Notional Amount	$ 105,000	$ 105,000
Index	LIBOR	LIBOR
Rate (as a percent)	1.24%	1.24%
Derivative liabilities	$ (1,073)
Derivative assets		$ 427
Swap at 4.98%
Derivative
Notional Amount	$ 25,480	$ 26,092
Index	LIBOR + 1.45%	LIBOR + 1.45%
Rate (as a percent)	4.98%	4.98%
Derivative liabilities	$ (2,224)	$ (2,157)
Swap at 4.98% | LIBOR
Derivative
Basis spread on variable rate (as a percent)	1.45%	1.45%
Swap at 4.04%
Derivative
Notional Amount	$ 6,135
Index	LIBOR + 2.25%
Rate (as a percent)	4.04%
Derivative liabilities	$ (243)
Swap at 4.04% | LIBOR
Derivative
Basis spread on variable rate (as a percent)	2.25%
Swap at 3.52%
Derivative
Notional Amount	$ 4,406
Index	LIBOR + 0.49%
Rate (as a percent)	3.52%
Derivative liabilities	$ (597)
Swap at 3.52% | LIBOR
Derivative
Basis spread on variable rate (as a percent)	0.49%

XML

Derivative Financial Instruments - Derivative Instruments Fair Value Table (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Derivatives, Fair Value
Asset Derivatives	$ 0	$ 427
Liability Derivatives	4,866	2,370
Not Designated as Hedging Instrument | Interest rate swaps | Receivables and other assets
Derivatives, Fair Value
Asset Derivatives	0	427
Not Designated as Hedging Instrument | Interest rate swaps | Derivative financial instruments
Derivatives, Fair Value
Liability Derivatives	$ 4,866	$ 2,370

XML

Derivative Financial Instruments - Derivative Offsetting (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Asset derivatives
Asset Derivatives	$ 0	$ 427
Amounts Subject to Enforceable Master Netting Arrangements	0	(427)
Net Amounts	0	0
Liability derivatives
Liability Derivatives	4,866	2,370
Amounts Subject to Enforceable Master Netting Arrangements	0	(427)
Net Amounts	$ 4,866	$ 1,943

XML

Stockholders' Equity and Partners' Capital - Textuals (Details)		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 25, 2016 $ / shares	Jan. 31, 2016 USD ($)	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) $ / shares	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) $ / shares shares	Dec. 31, 2015 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity issued during period					$ 492,500,000
Common Stock Offerings
Issuance of common stock, net					$ 417,163,000	$ 43,649,000
Share price (in usd per share) | $ / shares			$ 29.33		$ 29.33
Common Stock Dividends
Dividends declared (in usd per share) | $ / shares			$ 0.300	$ 0.295	$ 0.890	$ 0.875
LTIP Units
Incentive Plan
Number of forfeited units (in units) | shares							225,000
Restricted Common Stock
Incentive Plan
Number of forfeited units (in units) | shares					24,391	21,378
Nonvested awards, total compensation cost not yet recognized			$ 10,200,000		$ 10,200,000
Period for recognition (in years)					2 years
Restricted Common Stock | General and Administrative Expense
Incentive Plan
Compensation expense			$ 2,100,000	$ 1,400,000	$ 5,100,000	$ 4,500,000
2006 Incentive Plan
Incentive Plan
Number of shares authorized (in shares) | shares			5,000,000		5,000,000
Number of shares available for grant (in shares) | shares			1,921,610		1,921,610
Subsequent Event
Common Stock Dividends
Dividends declared (in usd per share) | $ / shares	$ 0.300
ATM
Common Stock Offerings
Issuance of common stock, net					$ 122,900,000
Share price (in usd per share) | $ / shares			$ 27.82		$ 27.82
Issuance of common stock, net (in shares) | shares					4,418,571
Remaining amount of shares available for issuance			$ 177,100,000		$ 177,100,000
ATM | Maximum
Common Stock Offerings
Maximum amount of common stock authorized		$ 300,000,000
Public Offering
Common Stock Offerings
Issuance of common stock, net					$ 297,800,000
Share price (in usd per share) | $ / shares			$ 30.64		$ 30.64
Issuance of common stock, net (in shares) | shares					9,720,000
Healthcare Trust of America Holdings, LP (HTALP)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend distribution ratio					1
Common Unit Offerings
Issuance of limited partner units in connection with an acquisition (in units) | shares					2,650,409
Issuance of partnership units in connection with an acquisition					$ 71,754,000
Common Stock Dividends
Dividends declared (in usd per share) | $ / shares			$ 0.300	$ 0.295	$ 0.890	$ 0.875

XML

Stockholders' Equity and Partners' Capital - Restricted Common Stock Activity (Details) - Restricted Common Stock - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Restricted Common Stock
Balance as of beginning of period (shares)	487,850	463,050	463,050
Granted (shares)	417,110	221,076
Vested (shares)	(236,749)	(135,213)
Forfeited (shares)	(24,391)	(21,378)
Balance as of end of period (shares)	643,820	527,535	487,850
Weighted Average Grant Date Fair Value
Balance as of beginning of period (usd per share)	$ 23.13	$ 20.90	$ 20.90
Granted (usd per share)	29.82	26.57
Vested (usd per share)	23.27	21.89
Forfeited (usd per share)	25.93	22.70
Balance as of end of period (usd per share)	$ 27.35	$ 22.88	$ 23.13

XML

Fair Value of Financial Instruments - Assets and Liabilities at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Assets:
Derivative financial instruments, asset	$ 0	$ 427
Liabilities:
Derivative financial instrument, liability	4,866	2,370
Fair Value, Measurements, Recurring
Assets:
Derivative financial instruments, asset	0	427
Liabilities:
Derivative financial instrument, liability	4,866	2,370
Fair Value, Measurements, Recurring | Level 1
Assets:
Derivative financial instruments, asset	0	0
Liabilities:
Derivative financial instrument, liability	0	0
Fair Value, Measurements, Recurring | Level 2
Assets:
Derivative financial instruments, asset	0	427
Liabilities:
Derivative financial instrument, liability	4,866	2,370
Fair Value, Measurements, Recurring | Level 3
Assets:
Derivative financial instruments, asset	0	0
Liabilities:
Derivative financial instrument, liability	$ 0	$ 0

XML

Fair Value of Financial Instruments - Assets on Nonrecurring Basis (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2016
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	$ 547,000	$ 0
Impairment on property being marketed for sale	900,000
Level 1
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	0
Level 2
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	547,000
Level 3
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	$ 0

XML

Fair Value of Financial Instruments - Textuals (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Debt, fair value	$ 1,781,600	$ 1,619,700
Debt, carrying value	$ 1,712,598	$ 1,590,696

XML

Per Share Data of HTA (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Net income		$ 6,639	$ 6,554	$ 30,191	$ 22,984
Net income attributable to noncontrolling interests	[1]	(212)	(91)	(830)	(425)
Net income attributable to common stockholders/unitholders		$ 6,427	$ 6,463	$ 29,361	$ 22,559
Denominator:
Weighted average shares outstanding - basic		138,807	126,863	134,905	125,750
Weighted average number of shares/units outstanding — diluted		143,138	128,793	138,314	127,680
Earnings per common share - basic
Net income attributable to common stockholders (in usd per share)		$ 0.05	$ 0.05	$ 0.22	$ 0.18
Earnings per common share - diluted
Net income attributable to common stockholders (in usd per share)		$ 0.04	$ 0.05	$ 0.21	$ 0.18
HTA, Inc.
Numerator:
Net income		$ 6,639	$ 6,554	$ 30,191	$ 22,984
Net income attributable to noncontrolling interests		(212)	(91)	(830)	(425)
Net income attributable to common stockholders/unitholders		$ 6,427	$ 6,463	$ 29,361	$ 22,559
Denominator:
Weighted average shares outstanding - basic		138,807	126,863	134,905	125,750
Dilutive shares		4,331	1,930	3,409	1,930
Weighted average number of shares/units outstanding — diluted		143,138	128,793	138,314	127,680
Earnings per common share - basic
Net income attributable to common stockholders (in usd per share)		$ 0.05	$ 0.05	$ 0.22	$ 0.18
Earnings per common share - diluted
Net income attributable to common stockholders (in usd per share)		$ 0.04	$ 0.05	$ 0.21	$ 0.18

[1] Includes amounts attributable to redeemable noncontrolling interests.

XML

Per Unit Data of HTALP (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Net income		$ 6,639	$ 6,554	$ 30,191	$ 22,984
Net income attributable to noncontrolling interests	[1]	(212)	(91)	(830)	(425)
Net income attributable to common stockholders/unitholders		$ 6,427	$ 6,463	$ 29,361	$ 22,559
Denominator:
Weighted average units outstanding - basic		138,807	126,863	134,905	125,750
Weighted average number of shares/units outstanding — diluted		143,138	128,793	138,314	127,680
Earnings per common unit - basic:
Net income attributable to common unitholders (in usd per share)		$ 0.05	$ 0.05	$ 0.22	$ 0.18
Earnings per common unit - diluted:
Net income attributable to common unitholders (in usd per share)		$ 0.04	$ 0.05	$ 0.21	$ 0.18
Healthcare Trust of America Holdings, LP (HTALP)
Numerator:
Net income		$ 6,639	$ 6,554	$ 30,191	$ 22,984
Net income attributable to noncontrolling interests		(1)	(20)	(28)	(77)
Net income attributable to common stockholders/unitholders		$ 6,638	$ 6,534	$ 30,163	$ 22,907
Denominator:
Weighted average units outstanding - basic		143,137	128,793	138,314	127,781
Dilutive units		0	0	0	0
Weighted average number of shares/units outstanding — diluted		143,137	128,793	138,314	127,781
Earnings per common unit - basic:
Net income attributable to common unitholders (in usd per share)		$ 0.05	$ 0.05	$ 0.22	$ 0.18
Earnings per common unit - diluted:
Net income attributable to common unitholders (in usd per share)		$ 0.05	$ 0.05	$ 0.22	$ 0.18

[1] Includes amounts attributable to redeemable noncontrolling interests.

XML

Supplemental Cash Flow Information (Details) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Supplemental Disclosure of Cash Flow Information:
Interest paid	$ 39,321	$ 39,570
Income taxes paid	934	790
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accrued capital expenditures	2,868	1,833
Debt and interest rate swaps assumed in connection with an acquisition	21,156	0
Dividend distributions declared, but not paid	$ 43,530	$ 37,712
Issuance of operating partnership units in connection with an acquisition	71,754	0
Note receivable included in the consideration of a disposition	$ 3,000	$ 0
Redeemable noncontrolling interest assumed in connection with an acquisition	5,449	0
Redemption of noncontrolling interests	$ 5,709	$ 0